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Preface 
Nanotechnology is an emerging technology that will have great impact on product innovation in the 
coming years. Currently the technology is already used in innovative cosmetic and medical products. In 
the food industry there is a clear potential for product and process innovation using nanotechnology and 
nanoparticles. This is exemplified already now by the availability of food products developed by making 
use of nanotechnology. 
 
It is however the societal responsibility of industry, governments and researchers to get inside in 
potential risks of the application of this evolving technology. The smaller the particles are the closer they 
come to the size/structure of natural barriers in nature and our body. Since we currently do not know 
what this means for the natural barrier functions we can not simply extrapolate our knowledge on the 
safety of micro- and macro structures and delivery systems to their nano-sized equivalents. 
 
Consumer acceptance of new products or products produced with new technologies has had serious 
dents in recent years at the introduction of food irradiation technology and genetic modification 
technology. Consequently both risk evaluation and consumer perception are important issues to be 
addressed in parallel with the development and application of new technologies. Disregarding these 
aspects could have dramatic negative aspect not only on the introduction of nanotechnology but also 
more in general to public perception of new technologies and product innovation. 
 
As a start in this process the Dutch Food and Consumer Product Safety Authority has asked RIKILT-
Institute of Food Safety, Wageningen UR and the National Institute for Public Health and the 
Environment to perform an inventory study on the current use of nanotechnology in food products and 
give advise on the most relevant safety evaluation issues. This report describes the results of this study.  
The report is set up in two parts. First you will find an aggregation of the results in the answer to 10 
questions. In this part you will also find our suggestions for prioritizing the research that is needed. The 
second document is a scientific background document. 
 
We hope that this report will be a stimulus for the various stakeholders in the process of a responsible 
development of this technology in facilitating the necessary research and risk evaluation.  
 
Robert van Gorcom André Henken 
Dept. Director RIKILT - Institute of Food Safety Director Division Food, Medicines and 
Consumer Safety - RIVM 
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Abstract 
In the food production chain nanotechnologies will impact food security, packaging materials, delivery 
systems, bioavailability, and new materials for pathogen detection, thereby contributing to the targets set 
for achieving the UN Millennium Development Goals. Already yet, food products containing 
nanoparticles  are penetrating the market, with a prominent role for sales via the Internet. This implies 
that regulatory frameworks and risk assessment should meet criteria for both pre- and post-marketing 
situations.  
As with most new and evolving technologies, potential benefits of nanotechnologies for agriculture, 
food industry and consumers are emphasized. However, little is known on safety aspects of the 
application of nanotechnologies in food production and the incorporation of nanoparticles in food 
products. Therefore, there is  a need for swift actions by policy makers and scientists as regulatory 
frameworks seem to need adaptation and scientists should give input for these adaptations. Their joint 
actions should facilitate the process of minimizing the health and environmental risks, while stimulating 
the economic developments of nanotechnologies in the food production chain.  
This report gives an overview and an advice for priority of scientific issues that need to be addressed in 
order to improve the process of  risk assessment for nanoparticles in food and in order to gain insight in 
dossier requirements for nanoparticles in food. The following research topics are considered to 
contribute pivotally to risk assessment of nanotechnologies and nanoparticles in general and thus also 
for applications in food products. 
• Characterization of nanoparticles. The particles have novel properties compared to conventional1 
chemicals. It is important to characterize these properties to enable  realistic estimations of 
consumer exposure. But equally important, this information is needed to establish dose-response 
relations in toxicology studies. Thus, analytical tools need to be developed for the isolation and 
characterization of nanoparticles in food and biological matrices. 
• Dose metrics. This is a very basic issue which affects both interpretation of scientific studies as well 
as regulatory frameworks. It has become clear that doses of nanoparticles and thus also limit values 
for nanoparticles cannot be expressed in weight or volume measures as is the case for conventional 
chemicals. Questions arise whether nanosized particles of their conventional counterparts need their 
own limit values.  
• Effects of nanoparticles. The kinetics of nanoparticles may be different compared to conventional 
chemicals. When there is evidence for uptake, distribution of nanoparticles should be studied more 
extensively when compared to their conventional counterparts. Of special importance are those parts 
of the body that are normally protected by barriers like the blood-brain-barrier and placenta.  
• Definition of nanoparticles. This is not only a formal issue for regulators but also very important for 
discussion on prioritization of research and exchange of study results between scientists, producers 
and regulators. 
• Consumer exposure to nanoparticles. It needs to be studied which products containing nanoparticles 
are on the market and which type of particles are used, and are being developed. 
Specifically for applications of nanoparticles and nanotechnologies in food products are the following 
issues thought to be relevant: 
• Oral bioavailability 
• Measurement of nanoparticles in food matrices 
                                                     
1
 Convential meaning not nano-sized 
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The proposed research issues should contribute to the development of safe nanotechnology and thus 
stimulating the economic developments of nanotechnologies. Products containing or generated by means 
of nanotechnology are already available on the market. It is evident that safety is in the first place the 
producers’ responsibility, however involvement of all relevant stakeholders will be required to protect 
consumers adequately. 
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Part A.  
Health impact of nanotechnologies in food production: 
Food safety issues of nanotechnologies in 10 questions 
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Introduction 
Nanotechnologies have the potential to contribute to the targets set for achieving the UN Millenium 
Development Goals, particularly in the areas of affordable energy, clean water, human health, and the 
environment. To bring these promises to fruition, public research programmes have an important role to 
play in providing greater incentives and encouragement for nanotechnologies that support sustainable  
development [UN Geo Year Book 2007].  
Nanotechnology has also the potential to impact many aspects of food and agricultural systems. Food 
security, packaging materials, disease treatment, delivery systems, bioavailability, new tools for 
molecular and cellular biology and new materials for pathogen detection are examples of the important 
items that are linked with nanotechnology within the food production chain (Chen et al. 2006a; Weiss et 
al. 2006). Food products containing nanotechnologies are penetrating the market, albeit currently 
predominantly outside the EU (e.g. Japan, China and the USA). It is however widely anticipated that 
they will appear on the EU market in the next few years. Currently many products containing 
nanotechnologies are of course globally available due to sales via the Internet. 
As with most new and evolving technologies, much emphasis is on the potential benefits of 
nanotechnology for agriculture, the food industry and likely the consumer. However, not too much is 
known on safety aspects of the application of nanotechnologies in food production and the incorporation 
of nanoparticles (NPs) in food products (Maynard 2006). The rapid emerging of nanotechnology creates 
therefore a need for swift action by policy makers. Their actions should facilitate the process of 
minimizing the health and environmental risks. As nanofood products are already on the market and 
uncertainty about potential risks is large, the need for science-based adaptation of the regulatory 
frameworks is high.  
The aim of this report is to identify knowledge gaps in the expertise needed to make reliable safety or 
risk assessments for consumer health in case of application of nanotechnology in food production.  
To this end first a inventory of products containing nanotechnologies that are currently on the market has 
been made. In addition an overview of the current knowledge on the potential hazards of NPs has been 
made based on a review of literature. This resulted in a background report, including detailed 
discussions on specific topics. Discussion with experts in toxicology, and on the general experimental 
requirements for dossiers to be submitted for risk and safety assessment of chemicals resulted in the 
development of a synthesis document.  
Outline 
The synthesis document is the first part of this report. On the basis of 10 questions covering the most 
important food safety issues of nanotechnology, knowledge gaps are identified, research issues named 
and potential impact of research outcomes on quality of risk assessment and regulatory framework 
identified. Subsequently, this information is applied for formulating a proposal for prioritizing research 
issues. Within this document reference is made to the second part of this report: the background 
document. There a scientific background is provided to the identified knowledge gaps. The background 
document provides an overview of the current-state-of-the-knowledge, without prioritization. 
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1  In which parts of the food chain are nanotechnologies applied? 
Nanotechnology tools are used in the entire food production chain e.g. during cultivation (e.g. 
pesticides), industrial processing or packaging of foods. In addition nanotechnologies are being used to 
enhance the nutritional aspects of food by means of nanoscale additives and nutrients and nanosized 
delivery systems for bioactive compounds (background document; section 3.2:Overview of 
applications).  
A striking observation is that nanotechnologies are being used throughout all phases of food production 
(Table 1). It has become clear that for applications of nanotechnology in food roughly two classes of 
application can be distinguished based on the likelihood of consumer exposure to nanoparticles (NPs) or 
residues of nanotechnologies applications. In the first class, nanotechnology is applied as a production 
tool, implying that no addition of NPs to the food will take place. Examples of this type of 
nanotechnology are the use of nanosieves (e.g. to filter out bacteria) or of hand-held devices containing 
nanotechnology for monitoring purposes. More in contact with food are sensors applied in food 
packaging materials. In the second class potential consumer exposure to NPs can be expected because 
NPs are purposely introduced into the food during the production. 
 
Table 1. Summary of applications of nanotechnology in the food production chain 
Chain phase Application Nanotechnology Function 
Nanospray on food commodities Binds and colors micro organisms 
Hand-held devices Detection of contaminants etc. 
Agricultural 
production 
Nanosensors 
Incorporated in packaging materials Detection of food deterioration. 
Nanoemulsions, -encapsulates Increased efficacy, water solubility and 
crop adherence 
 Pesticides 
Triggered release nanoencapsulates Triggered (local) release 
Filters with nanopores Pathogen/ contaminant removal  Water purification/ 
soil cleaning Nanoparticles Removal or catalysation of oxidation of 
contaminants 
Food production Nanoceramic devices Large reactive surface area Production and 
processing of 
food 
Refrigerators, 
storage containers, 
food preparation 
equipment 
Incorporated nanosized particles, 
mostly silver, occasionally zinc 
oxide 
Anti-bacterial coating of storage and 
food handling devices 
Food products Nanosized silver sprays Anti-bacterial action 
Incorporated sensors Detection of food deterioration. 
Monitoring storage conditions 
Incorporated nanoparticles Increasing barrier properties, strength of 
materials 
Conservation 
Packaging 
materials 
Incorporated active nanoparticles Oxygen scavenging, prevention of 
growth of pathogens 
Colloidal metal nanoparticles Claimed to enhanced desirable uptake 
Delivery systems "Nanoclusters" Protecting and (targeted) delivery of 
content 
’Functional 
food’, 
consumption 
Supplements  
Nanosized/-clustered food/drinks 
(nutrients) 
Claimed enhanced uptake 
In Annex I an overview of currently available products can be found. 
 
In the second class a diversity of NP types is currently applied in the food production chain, which can 
be divided in inert particles and nanodelivery systems. Inert particles are used in the food production 
chain (Table 2) for a variety of purposes. Examples are aluminum oxide, lanthanum particles and 
nanoscale iron powder in the process of water purification and/or soil cleaning. In food storage, silver 
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and in rarer cases zinc oxide NPs are applied. Silicate NPs, nanocomposite and silver, magnesium- and 
zinc oxide are used in food packaging materials. Inert NPs are also processed in food commodities 
examples are calcium, magnesium, silver, silicate, silicium oxide and white gold NPs. Other applications 
in food commodities are nanosized particles, regulatory peptides from plants, nanodroplets/- clusters and 
nanowater (see Table 2). The aim of nanosizing the particles is to increase the bioavailabity of these 
compounds.It is important to note that the characteristics of abovementioned particles are usually 
unknown (background document; section 3.3: Description of types of nanoparticles). 
Consumer exposure can be expected following direct application of inert particles in the food, while 
expected consumer exposure is low as long as NPs remain bound in the packaging materials or in the 
coating on surfaces of packaging materials and food preparation devices. Crucial safety-related issues 
are migration NP resulting in appearance (e.g. free or as large aggregates) of these NPs in the food. As 
stated before, especially the free forms of the NPs are reason for safety concern (SCENIHR 2006). 
The other type of NPs concerns the nanodelivery systems (Letchford and Burt 2007; Taylor et al. 2005). 
When incorporated into food the delivery systems are commonly build from peptide or lipid monomers 
(Chen et al. 2006b; Graveland-Bikker and de Kruif 2006; Mozafari et al. 2006). Examples of these 
nanoencapsules (see Table 2)  range from novel pesticide formulations (e.g. increased crop adherence) to 
delivery systems for bioactive compounds. These novel formulations may lead to increased human 
exposure as a result of increased residues in plants. The other major application of encapsulates is 
incorporation in food (supplements) to deliver bioactive compounds in a targeted fashion and to increase 
the bioavailability of these compounds.  
 
Table 2: Summary of type of nanoparticles applied in the food production chain 
Type of NP Application Function 
Colloidal metal 
nanoparticles 
Food additive Claimed to enhance desirable GI-uptake  
Food additive/supplement Claimed enhanced uptake 
Packaging materials/ storage Increase barrier properties 
Food preparation devices Clean surface 
Refrigerators, storage containers Anti-bacterial coating of storage and food handling 
devices 
Water purification/ soil cleaning Removal or catalysation of oxidation of contaminants 
Metal nanoparticles (Silver, 
ZnO) 
Sprays Anti-bacterial 
Nanosized nutrients /foods Food additive /supplement Claimed enhanced uptake 
Nanosensors in packaging Detection of food deterioration. 
Monitoring storage conditions 
Complex nanoscale 
structures 
Hand-held devices Detection of contaminants etc. 
Incorporated active 
nanoparticles 
(migration out of) packaging 
materials 
Oxygen scavenging, prevention of growth of 
pathogens 
Filters with nanopores Water purification Removal pathogens, contaminants 
 Equal emulsions Product design 
Food additive / supplement Protecting and (targeted) delivery of content Delivery systems 
(nanoencapsulates) Pesticide Increased efficacy, water solubility and crop 
adherence, triggered (local) release 
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Knowledge gaps 
The assessment of potential risks of applications of nanotechnologies in agriculture, like residues in food 
products, of leakage from packaging materials and of nanoscale food additives, and supplements will 
require substantial scientific input. There is a lack of knowledge on the exact characteristics of the 
applied NPs and consequently a lack of knowledge on potential consumer exposure. The wide 
application of nanotechnology within the food chain will have as a consequence that various regulatory 
frameworks (see question 5) will need to be reviewed for their validity. Regulatory and scientific efforts 
will have to be carried out both in the light of pre- and post marketing situations.  
 
Research issues/potential impact of research  
• Proper definition of (bio)nanotechnology and nanoparticles applied in food production: One of 
the basic problems when discussing safety aspects of nanotechnology is the diversity of 
nanotechnologies and NPs (e.g. from inert insoluble nanoparticles to delivery systems for pesticides 
and bioactive compounds). A practical definition will serve as a guide towards prioritization of 
research as well as towards producers and regulators as a guide for dossier requirements. In addition 
it is of paramount importance for a transparent discussion with stakeholders and the public (see 
question 2). 
• Overview of type of nanotechnology containing products already on or expected to be 
introduced on the market. The advantages of having an accurate overview are discussed under 
question 3. 
• Inventory of scientific requirements for pre- and postmarketing situations: To adequately assess 
the safety of products during an authorization procedure or assess the risks of products already on 
the market, knowledge needs to be gained on various aspects of NPs in food (see question 6 and 
question 7). By gaining more knowledge and experience with respect to NPs the reliability of the 
current safety and risk assessment will be improved. The inventory itself will be helpful in 
prioritizing research activities.  
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2 Is a lack of a strict definition a problem? 
The answer can be given easily: it is a clear “yes”.  
There is a commonly used definition which states that engineered nanoparticles (NPs) are materials that 
are designed and produced to have structural features with at least one dimension of 100 nanometers or 
less (Oberdorster et al. 2005a). Thus nanotechnology involves the manufacture, processing and 
application of materials that are in the size range of 100 nanometers (nm) or less. The size limit once 
was chosen defined from a more physico-chemical point of view, but not on a toxicological basis. 
In international fora like Scientific Committee on Emerging and Newly-Identified Health Risks 
(SCENIHR) and the International Organization for Standardization (ISO) discussions on definition are 
high on the agendas. However, most discussions lead in the direction of defining the upper size limit of a 
NP is as approximately 100 nm, which is not strict enough for application in regulatory frameworks.  
Another important definition issue is the lack of good metrics to describe a dose of NPs. It has become  
clear that the currently used metrics for concentration (e.g. mg/kg) are no longer adequate. Up till now it 
has not been possible to establish an alternative dose-describing parameter that best describes the dose 
(and the observed dose response relations in toxicological tests). This has led in literature to a general 
recommendation that NPs used for (toxicological) studies should be characterized as completely as 
possible (Oberdorster et al. 2005a; Powers et al. 2006; Thomas and Sayre 2005). It has become clear that 
the size will not be the only critical factor to consider, the total surface area may also be relevant, as well 
as the number of particles per particle size and perhaps other characteristics (background document; 
section 4.1:Physicochemical characterization of nanoparticles).  
 
Knowledge gaps 
The exact size limit of 100 nm in the present definition of NPs is arbitrary due to lack of knowledge on 
the relationship between particle size, kinetics and toxicological effects. It will be relevant to explore the 
legal feasibility of avoiding arbitrary size limits, in order to handle the consequences of scientific 
uncertainties in a more pragmatic way. Such knowledge is not easily derived. Thus, the definition should 
therefore first be treated in a pragmatic way.  
In contrast to conventional2 chemicals exposure to NPs means exposure to particles that cover a certain 
range of sizes. Moreover, particles can have a variety of shapes. These two issues already imply that 
doses cannot be described on a weight or volume basis, but it is also to simple to assume that a one 
dimensional parameter like surface area can be a good substitute. Probably, multifactorial units, taking 
into account e.g. the number of particles of a certain size and surface area will need to be developed. 
 
Research issues/potential impact of research  
• Propose a ‘working’ definition of nanoparticles: Several international working groups 
(SCENIHR, ISO) are considering definitions of nanotechnologies and NPs that are adequately 
describing the novel nature of the NPs and on the other hand are practical from a regulatory point of 
view. A proper definition, i.e. applicable in regulatory frameworks, will give clarity for both 
producers and regulators. 
Knowledge on dose-describing parameters can feed these discussions. A proper dose metrics will 
help researchers to compare study results and will help regulators to formulate health-based limit 
values. It will also enable risk assessors to compare and combine exposure and hazard information 
and conclude on the likelihood of health risks. 
                                                     
2
 Convential meaning not nano-sized 
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3 What products are already on the market?  
Food products containing nanotechnologies are penetrating the market, albeit currently predominantly 
outside the EU (e.g. Japan, China and the USA). It is widely anticipated that they will appear on the EU 
market in the next few years. Currently many nanoproducts are globally available a.o. due to sales via 
The Internet. But not all applications and not all nanoparticles (NPs) are alike and thus they do not share 
the same hazard or risk profile. A ranking of risks given the application and type of NPs should be made.  
An integrated inventory of applications of nanotechnologies and NPs in food has been made. This 
inventory has been made using Google™ 3, the database of consumer products of the Nanotechnology 
project (www.nanotechproject.org) of the Woodrow Wilson International Center for Scholars, in the 
Global New Products Database of Mintel (www.gnpd.com), the Nanotechnology Product Directory 
(www.nanoshop.com) and the report of nanoforum (www.nanoforum.org).  
The results of this inventory can be found in Annex I of the background document. As stated before 
applications can be found throughout the food production. Products claimed to contain nanotechnology 
are used in the food processing and storage and applied directly in food commodities (Table 3). 
 
Table 3: Summary of number of products per class of application in the inventory 
Class of application Number of products 
Nanosensors 2 
Pesticides 5 
Water purification /soil cleaning 5 
Food processing and storage 10 
Food packaging 7 
Food commodities: inert particles 9 
Food commodities: delivery systems 19 
Food commodities: others 9 
The number of products per class of application are based on the inventory presented in annex I of the 
background document. 
 
Knowledge gaps 
The inventory is based on labeling information on the product as provided. The claim that these products 
contain nanotechnology cannot be verified from the information presented. This also applies to the 
information on the presence and/or type of NPs in these products. It can be expected that the claim 
‘nanotechnology’ on the label of some products is not more than a marketing instrument. Probably even 
more critical is the fact that products containing nanotechnology or NPs that are not claimed on the 
labels are for that reason not included in this inventory. Thus instruments needs to be developed for the 
control of labeling information and validation of databases.  
 
                                                     
3
 using the search terms ‘nano’, ‘nanotechnology’, ‘nanotubes’, ‘nanoparticles’, ‘food’, ‘product’ in varying 
combinations 
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Research issues/potential impact of research  
• Developing an integrated quality-checked database: The inventory of this project could result in 
a database existing of nanotechnology containing foods. This database could be extended with a 
patent database (as developed by DEFRA / CSL in the United Kingdom). Quality of information of 
overviews on economic perspectives and developments made by consultancy agencies should be 
evaluated. 
High-quality and reliable databases can be used to obtain a realistic view on products on the market 
and can thus used for monitoring purposes, priority settings for post-marketing surveys and 
emerging risk projects.  
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4 What can be expected to reach the market in the (near) future? 
It is difficult to predict accurately the long-term trends of nanotechnology within the agriculture and 
food industry. Nearby trends will favor those nanotechnologies and application of those NPs that are 
readily available, for example applications using nano-scale metals, polymers, silica and commonly 
applied encapsulates. Furthermore, trends in applying nanotechnology in food are likely to be driven by 
social priority areas to large-value commercial or public sector markets such as human health, 
agriculture and environment (DEFRA 2005). 
Within agriculture, precision farming has been a long-desired goal, making use of smart sensing systems 
for early warning of e.g. moisture changes, but also nanodelivery systems for pesticides that are able to 
respond to different conditions. First examples of such applications have been found in the database 
search (see question 3). Within food industry research on the application of NP in packaging materials 
aimed at developing smart packages will continue. A development to couple sensing systems to radio 
frequency identification technology (and thus linking packaging and logistic processes) can be foreseen. 
While costs of these systems are currently the main drawback, fusions of nanotechnology and 
electronics should make these transponders cheaper (Nanoforum 2006). 
The consumer products databases mention also products that aim at improving the nutritional value of 
food products. An example is biofortification aiming to reach the most vulnerable, rural poor. 
Nanotechnology may enhance trace element delivery (M.B. Zimmerman, inaugural speech WUR, 2007). 
A next step, that is currently under research, is the development of functional or interactive foods (“on 
demand” foods), containing nutrients which will remain dormant in the body and deliver nutrients to 
cells only when needed. A key element is the use of nanoencapsulates (or nanocontainers) in food to 
deliver nutrients. Products like this, containing nanoencapsulates loaded with nutrients or bioactive 
compounds, will help to enjoy food but still maintain for example a healthy and or low calorie diet. 
These novel applications will contribute to the role of foods in preventive healthcare (Kampers 2007). 
There is a development of lowering the boundaries between the food and cosmetical domain or between 
food and pharma, where for example both food and cosmetic industries are developing methods to 
deliver vitamins to the skin (Nanoforum 2006). 
 
Knowledge gaps 
Technological developments and applications of new nanotechnologies and nanoparticles in food will 
continue. As stated under question 3 regularly updated quality-checked databases are of high value to 
obtain a realistic view on products on the market. 
Most agricultural and food applications of nanotechnology will be subjected to some form of approval 
process before a marketing authorization. The adequacy of the current regulatory framework has been 
reviewed and will be discussed under question 5. The general problems identified there will also be 
relevant for future developments of nanotechnology, e.g. whether food processed at nano-scale should 
be considered as novel foods. Integration or disappearance of boundaries between types of application 
(cosmetics, medicines and food) will result in possible aggregated exposure of NPs, consequently this 
has to be considered in the safety assessment of NPs. 
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5 Which regulatory frameworks might be involved? 
The EU’s approach to nanotechnology is ‘safe, integrated and responsible’ [Eva Hellsten in a Green 
Week session on ‘Future Scenarios for Human Health and the Environment’, June 13. 2007]. To that end 
the EU has commissioned the Scientific Committee on Emerging and Newly-Identified Health Risks 
(SCENIHR) to make an inventory to check whether nanotechnologies are already covered by other 
community legislation, thus defining the legislative framework, considering both implementation and 
enforcement tools for this specific framework. It was concluded that the EU regulatory framework 
covered in principle also nanotechnologies. The Health Council of the Netherlands considered that: “the 
best course of action would be to modify existing laws and rules as and when developments within the 
fields of nanoscience and nanotechnologies render such measures necessary” 
(HealthCouncilNetherlands 2006 ). However, it is also clear that implementation of the legal framework 
remains difficult because of scientific knowledge gaps and fast-evolving market for products.  
 
In this report the most important regulatory frameworks for the authorization of compounds to be used 
in food have been reviewed: 
• The European General Food Regulation (EC/178/2002) 
• Novel food [and novel food ingredients] Regulation (EC/258/97) 
• Food additives, enzymes and flavorings (89/107/EC; 94/36/EC; 94/35/EC; 95/2/EC and their 
amendments). 
• Food enrichments regulation (EC/1925/2006) 
• Food supplements directive (2002/46/EC) 
• Food contact materials (EC/1935/2004) 
• And regulations and directives on pesticides and veterinary drugs. 
 
Knowledge gaps 
Authorization procedures, legislation, guidelines and guidance documents describe how and which 
toxicity tests should be performed. Adjustments of legislation, guidelines and guidance documents 
concerning the testing of nanoparticles (NPs) of the substance are considered to be necessary. In 
particular requirements on information of the physico-chemical parameters, e.g. particle size, particle 
form, surface properties and other properties that may have impact on the toxicity of the substance, 
should be included. Furthermore, appropriate dose metrics to use in the hazard characterization and 
consumer exposure assessments should be developed (background document; section 5: Review of food 
related legislation related to nanotechnology in food).  
Methodological changes in (OECD) safety test protocols may be required to account for toxicity 
mechanisms of NPs not found in 'normal sized' materials. Thresholds or limits already set may be not 
appropriate for nanosized variants of the particular substances. 
The review of the regulatory framework demonstrated that the impact of considering nano-sized 
materials as 'new substances' should be investigated. If a substance in its conventional form has been 
evaluated, re-evaluation of the nano-sized form may be necessary. One should be aware, that each new 
nano-sized form of a certain chemical probably has to be considered as a separate  new compound, as 
long as size-effects relationships are not established for that compound. This underscores the need for 
taking into account the effect of particle size (including distribution of the size) in toxicological studies 
(see question 7). 
The Novel Food Regulation (EC/258/97) can be very relevant for nanotechnology in food. This 
regulation addresses 'production processes not currently used' making it is likely to assume that this 
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regulation covers also nanotechnology because of its novelty. It is not clear whether the use of NPs in 
foods that are already on the market makes these foods 'novel' and thus require authorization. 
Furthermore the term ‘substantial equivalent’ is introduced. The regulation says that when certain food 
components are 'substantial equivalent' to their conventional counterparts they can be treated in the same 
manner as their counterparts. Only the 'equivalency' has to be proven. It is likely that some engineered 
NPs will be 'equivalent’. The Novel Food Regulation is under revision at this moment, clearly an 
opportunity to sort out nanotechnology related issues (background document; section 5.2 : Novel food 
and novel food ingredients). 
 
Figure 1. depicts how knowledge gaps affect regulatory frameworks and safety requirements. 
 
 
 
Research issues/ Potential impact of research 
• In-depth analysis of relevant regulatory frameworks guidance document and technical 
annexes: How adequate is the current legislative system on food safety and novel foods regarding 
nanotechnologies. This contributes to the discussion whether there is a need for new legislation to 
deal with the safety aspects of nanotechnologies in food or if guidelines should be adapted to new 
scientific findings. It will gain insight in the actual adaptations that should be made and will 
complement the opinion of SCENIHR on the appropriateness of technical guidance documents for 
new and existing chemicals(SCENIHR 2007). Translation to what their conclusions mean in 
experimental settings and the relevance for food safety is required at the European level. It is 
important for both pre- marketing safety assessors as well as for producers to be clear on what is 
required to be able to convincingly determine the safety of products containing nanotechnologies 
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• Legal consultation: How to interpret legal phrases of the above mentioned EU regulatory 
frameworks on and consequences of interpretation of legislation. Clarification and unity of 
interpretation of terminology is important for reasons of transparency and common understanding 
(between safety assessor, regulators and producers). 
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6 Does safety testing for nanoparticles require more studies than safety 
testing for conventional chemical compounds? 
Engineered nanoparticles (NPs) can have novel or distinct (toxicological) properties that are attributed to 
a combination of their small size, physiochemical properties, chemical composition and surface structure 
(Nel et al. 2006). It is the added functionality of NPs that makes the engineered NPs different from 
natural small sized particles, but also from their conventional counterparts. 
Logically, present safety and risk assessment requirements are based on knowledge gathered for 
conventional chemicals. Also in these assessment assumptions have to be made because of knowledge 
gaps. However, uncertainties in these assumptions for example extrapolations from one compound to 
another are approached on a sound basis of general knowledge. For nanoparticles such a basis is lacking, 
moreover uncertainties in the safety assessment are expected to be larger (Morgan 2005).  
 
Knowledge gaps 
At this stage of (lack of) knowledge of nanotoxicology it is unavoidable that risk assessors need as much 
information as possible about NPs and their appearance in products. Over time it will be possible to 
evaluate the data and look for the set of most relevant information. Discussions between product 
developers, regulators and researchers can already be improved by accepting this as a fact. This request 
for extra information is not to be considered as a request for extra studies. It can also imply that 
conventional study approaches need to be redesigned.  
The lack of the most optimal dose metrics is an example of a situation where at this moment it is still 
necessary to gather data on a broad range of physical chemical properties. This will hopefully in future 
lead to the determination of the set of most relevant data requirements. 
The kinetics of nanoparticles may be different compared to conventional chemicals. When there is 
evidence for uptake, distribution of nanoparticles should be studied more extensively when compared to 
their conventional counterparts. Of special importance are those parts of the body that are normally 
protected by barriers like the blood-brain-barrier and placenta. In addition, there are indications that very 
small particles can intrude in tissues of the digestive tract like the salivary glands, which are not 
screened in standard toxicological surveys. It is however not clear from which size on it would be 
relevant to extend the toxicological surveys to extra endpoints. This is discussed further under question 
7. 
If the effects induced by NPs are in general comparable to effects induced by equivalent conventional 
substances, these will likely be observed in the toxicity studies performed to OECD guidelines. 
However, if other effects are critical, e.g. effects on organs or tissues that are not routinely studied or 
physiological disturbances that require specific examination, these effects may not be picked up by 
standard toxicological testing. To date, it is not known whether the standard toxicological study 
protocols (e.g. OECD) will be able to detect all specific hazards from NP. This relates to the knowledge 
gaps identified under question 7. 
It is clear that in the regulatory framework the responsibility for the safety of the product is assigned to 
the producers. There currently is a need for guidance on how to approach the safety assessment of NPs, 
and what information should be presented by producers to the regulatory agencies. To elucidate this a 
close collaborations between all stakeholders is required. 
 RIKILT /RIVM Report 2007.014 20 
7 Which safety and risk assessment issues need to be addressed for 
nanotechnology in food? 
Discussions on safety issues of nanoparticles (NPs) and nanotech products can almost entirely be 
brought back to two, often intertwining, questions: 
 
1. product related questions, e.g. which specific measurements are required in order to come to proper 
insight into safety of the product.  
2. fundamental scientific questions resulting in or based on the development of new conceptual 
approaches.  
 
Discussions on data requirements  and expected performance of current assays have demonstrated that it 
is important to focus the question on what information is additionally required to dossier requirements 
for conventional chemicals. Some research agendas or roadmaps try to circumvent uncertainties which 
are accepted in risk assessment of conventional chemicals. Questions like “are in vitro tests applicable 
for NPs” should rather be formulated as “are in vitro tests equally applicable for NPs as for conventional 
chemicals”, as the role of in vitro test results for chemical in risk assessment is still subject to many 
uncertainties.  
Another important way of focusing the discussion is to keep in mind what will really bring risk 
assessment to a higher level. In other words, in an area where such an enormous amount of research 
questions can be/ are raised, it is essential to define those questions that represent the ‘needs to know’. 
This approach should be leading in every kind of roadmap or research agenda that is developed for the 
field of potential risks of nanotechnology. 
A special group of NPs that are applied in food are the nanoencapsulates. The capsules (when applied in 
food) usually are composed of soft matter, that is generally assumed to be of lower risk than the above 
mentioned inert particles. In case of the nanoencapsulates safety concerns are mainly related to their 
function: e.g. to increase the bioavailability of specific bioactive compounds (or pesticides). What are 
the effects of increased bioavailability of these compounds? The high internal exposure of bioactive 
compounds as a result of increased bioavailability may lead to toxic effects . 
For risk assessment both information on exposure as well as on the (intrinsic) toxicity (hazard) of a 
compound is required. Determining potential consumer exposure is first of all important to assess the 
potential risk for consumers. Keeping in mind Paracelcus quote “Alle Ding sind Gift und nichts ohn 
Gift; allein die Dosis macht, das ein Ding kein Gift ist”(All things are poison and nothing (is) without 
poison; only the dose makes that a thing is no poison). Thus the dose of NPs present in food needs to be 
determined. As stated earlier, engineered NPs can have novel toxicological properties, that are attributed 
to their small size, chemical composition and surface structure (Nel et al. 2006). Since it has not been 
possible to establish a single dose-describing parameter that best describes the toxic effect, NPs should 
be characterized as completely as possible (Oberdorster et al. 2005a; Powers et al. 2006; Thomas and 
Sayre 2005). A further complicating factor is that the physico-chemical characteristics of NPs are highly 
depending on the matrix in which they are present (Oberdorster et al. 2005a; Powers et al. 2006). Thus 
urging the need to characterize NPs in the food matrix (e.g. in situ). 
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Knowledge gaps  
The knowledge gaps cover a wide range of topics which are summarized on the headings below.  
• Physicochemical properties of NPs as applied as starting material in the product and as manifested 
in the final product (background document; section 4.1: Physicochemical characterization of 
nanoparticles). 
• Dose metrics in dose response relations: Since it has not been possible to establish a single dose-
describing parameter that best describes the possible toxicity, NPs should be characterized as 
completely as possible (Oberdorster et al. 2005a; Powers et al. 2006; Thomas and Sayre 2005). It is 
likely that mass is not the good metric (SCENIHR 2006). As long as it is not known which metrics 
should be used to describe the dose, toxicity tests will have to be analyzed case by case using 
different dose-describing parameters. It is therefore important for risk assessors to have access to a 
clear description of the analytical methods that were used to determine the physicochemical 
properties of the respective NP, to the (raw) experimental data and a sound description of the 
statistical procedure used to analyze the data (background document; section 4.1: Physicochemical 
characterization of nanoparticles).  
• Assessment of exposure:  
o For exposure assessment of nanoscale delivery systems loaded with bioactive compounds or 
bioactive compounds themselves in nanoscale formulations, both the amount of bioactive 
compounds at nanoscale or within the capsules as well as the free form in the food matrix has to 
be determined. For this, the analytical isolation, detection and characterization procedures need 
to be designed to meet these requirements (background document; section 4.1: Physicochemical 
characterization of nanoparticles).  
o The presence of NP in the food matrix might result in increase bioavailability of substances 
normally present in the food (background document; section 4.4: Exposure assessment).  
o A prerequisite for an exposure assessment is the reliability of the concentration data. The 
amount and type of NPs, the type of nanodelivery system loaded with bioactive compounds and 
the amount of bioactive compound in the free from needs to be determined in the food matrix as 
consumed. It will not always be feasible to measure chemicals and NPs in the food matrix in the 
consumable form. However, the default or database derived processing factors that are being 
used for determination of exposure assessment of normal chemicals when the exact effect of 
processing is unknown, (e.g. pesticides (JMPR)), are not (yet) available for NPs (background 
document; section 4.4: Exposure assessment.  background document; section 4.5: Risk 
assessment). 
• Internal exposure: Experimental data so far indicate that novel characteristics of NPs (e.g. size, 
surface charge, functionalized groups) are likely to influence the absorption, metabolism, 
distribution and excretion (ADME) (Ballou et al. 2004; des Rieux et al. 2006; Florence 2005; Jani et 
al. 1990; Roszek et al. 2005; Singh et al. 2006) of NPs present in food. Not much is known of the 
relationship between these physical-chemical characteristics and the behavior of NPs in the body 
(background document; section 4.2: Toxicokinetis of nanoparticles). 
• Adverse effects: Knowledge on the potential toxicity of NPs is limited. Several studies suggest that 
NPs may have a deviating toxicity profile when compared to their conventional chemical analogues 
(Donaldson et al. 2001; Nel et al. 2006; Oberdorster et al. 2005a). As mentioned earlier, the question 
arises whether this different toxicity of NPs can be observed in the standard battery of toxicity tests 
used in protocol toxicology. It is thought that the standard battery will suffice, but special attention is 
requested for (background document; section 4.3: Toxicodynamics of nanoparticles). 
o Neurotoxicity, as results from ADME studies clearly indicate that some NPs can pass natural 
barriers like the blood-brain barrier (Borm et al. 2006; Silva 2007).  
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o Reprotoxicity, as transfer of NPs across the placenta cannot be excluded, which could lead to 
embryotoxicity as a result of exposure to NPs (Fujimoto et al. 2005). Data addressing the 
distribution of NPs to the reproductive cells is, as yet, unavailable. In addition, no clear data 
showing the distribution of NPs in the fetus are available (Tran et al. 2005). 
o Mutagenicity, as there are indications that on the cellular level, barriers such as cell membranes 
do not constitute obstacles for NPs. However, the health implications of such possible 
interactions are still unknown (Kabanov 2006)UBA 2006). Recently, SCENIHR (SCENIHR 
2007) concluded that there is a clear need for validated in vitro assays for NP evaluation, 
including assays with meaningful endpoints for genotoxicity tests.(background document;  
section 4.3.6) 
o Allergenicity (or sensitization). Even for conventional chemicals much is unknown on the 
induction of food allergy and the type of exposure required to induce such responses. In the case 
of NPs this becomes extra prominent for two reasons. First of all it is the possible adjuvant 
activity of NPs that introduces additional uncertainty. And secondly, because of the actively 
charged surfaces of NPs it can absorb biomolecules as they pass through the GI tract (Govers et 
al. 1994).(background document;  section 4.3.7) 
• Setting health based guidance values: The last step in the hazard characterization is the setting of 
health-based guidance values such as acceptable daily intakes for food additives and pesticide 
residues. Reference points (e.g. the no-observed-adverse-effect-level or benchmark-dose-level) for 
the critical effect of a substance form the starting point of the risk assessment. This is a general 
approach for all substances either being in a conventional form or at a nano-sized scale. It is 
however still unknown how limit values derived for NP’s can be compared to those of equivalent 
conventional chemicals, due to ongoing discussions on dose metrics (background document; section 
4.5: Risk Assessment).  
• Guidance values are based on toxicological studies performed with NPs with a given bioavailability. 
NPs are often introduced to enhance the bioavailability of either themselves or of bioactive 
compounds loaded into them or they may affect the uptake of other nutrients (or contaminants) 
present in the food. If by some means the bioavailability is changed (increased), this may affect the 
outcome of the toxicity studies and thus the calculated guidance values. Extrapolation of a health-
based guidance value between formulations with different bioavailability might not be possible. 
Ultimately, this might require setting of separate health-based guidance values depending on the 
formulation (background document; section 4.5: Risk Assessment).  
 
Research issues / potential impact of research 
When resolved the formulated research issues should increase the reliability of the current safety and 
risk assessment of NP in food even within a 5 year period.  
- The knowledge gained will help regulators to adapt the regulatory framework properly. 
- Development of analytical methods in combination with knowledge on toxicity will be essential 
for upholders 
- Reduction of present uncertainties will help to gain the public’s trust for this technology and its 
products. 
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• Physicochemical properties and stability in the product matrix:  
o At present there is a vast array of analytical techniques to characterize NPs (Oberdorster et al. 
2005a; Powers et al. 2006; Thomas and Sayre 2005). Often the physicochemical 
characterization requires a well-equipped laboratory. Literature on isolation of NPs from 
biological or food matrices is scarce as is the literature on in situ detection methods. Every 
dilution, extraction or cleaning procedure may affect the appearance of the NPs and result in an 
incorrect measurement of the NP in the matrix. Potentially this will have great impact on the 
safety assessment of NPs. It may lead to both false-positive or false-negative conclusions 
regarding potential exposure to NPs. 
Therefore research should focus on methods that are able of in situ detection and 
characterization of NPs, and that are relatively easily performed with apparatuses that are 
currently present at laboratories suited for detection of chemicals in food. Ideally, isolation and 
characterization methods should be developed, suitable for routine and low-cost analysis. 
o It is important to known which additional information regarding physicochemical properties 
(more than currently presented in dossier of conventional chemicals) will be needed in dossiers 
for an assessment of NPs in products.  
o A special case might be the NPs used in packaging materials. Current migration assays for 
chemicals will need to be evaluated for their validity in measuring the migration of NPs from 
the packaging material into the food.  
o Selecting the matrix in which the NP needs to be characterized is not an easy choice. The matrix 
should reflect the potential consumer exposure to a NP - food product as accurately as possible. 
• Dose metrics:  
o It has up to now not been possible to establish a single dose-describing parameter that best 
describes the (toxic) effects. A pragmatic basic set of characteristics should be developed that 
describes the dose well enough, e.g. size and size distribution and/or total surface area, and is 
also practically feasible with respect to analytical requirements. It is important to keep in mind 
that a dose of NPs contains a range of sizes of a certain type of NPs. This implies that 
information on mean particle size is not sufficient to describe a dose properly. Moreover a 
conceptual model for the most optimal unit describing a dose and based on a combination of 
physics, basic chemical characteristics and toxicological findings should be further developed. 
• Internal exposure: 
o The validity of currently existing in vitro model systems for the gastrointestinal absorption 
needs to be studies. 
o When there is evidence for gastrointestinal absorption of nanoparticles, distribution to a wide 
range of tissues should be studied (including the liver, spleen, kidneys, bone marrow, lungs and 
brain). Keeping in mind that generally only a few tissues and organs are examined in guideline 
kinetic (OECD) studies. The same holds true for the use of nanoencapsulates aiming at targeted 
delivery of bioactive compounds. Special attention is required in case of (increased) 
bioavailability and distribution to tissues that are normally protected by biological barriers such 
as the blood-brain barrier.  
o Furthermore there is a need for fundamental research on the absorption, distribution, metabolism 
and excretion (ADME) of NPs to elucidate the driving forces and mechanisms behind these 
processes. This would greatly facilitate the extrapolation and modeling approaches. However, if 
the current ADME studies are performed with adequately characterized NPs and a wide range of 
tissues are analyzed when there is evidence for systemic uptake sufficient information would 
become available for a reliable ADME assessment. 
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o Due to the potential impact on toxicological effects special attention needs to be paid to 
observations that certain NP can cross the blood-brain barrier and the data lack on potential for 
crossing the placenta.  
o Special attention is required for cellular kinetics in order to better understand and predict 
cellular toxicity and the validity of currently used in vitro models.  
• Adverse effects:  
o Neurotoxicity needs to be considered carefully when there is evidence for NP passage of the 
blood-brain barrier. Risk assessors should be aware of possible neurological effects when 
assessing toxicology experiments. Possibly, current guideline tests will need to be adapted to 
render these tests more sensitive for neurotoxic effects of NPs.  
o Reprotoxicity and embryotoxicity needs to be considered carefully when there is evidence for 
NP passage of the placenta. This is not only relevant for inert NPs but also for bioactive 
compounds that are loaded within nanoencapsulates. 
o Mutagenicity. Develop and validate in vitro assays for the gastero-intestinal tract. Many NPs 
have in common to trigger the release of reactive oxygen species and cause oxidative stress by 
means of interaction with the reticulo-endothelial system (Donaldson et al. 2007; Nel et al. 
2006). Model systems for testing genotoxic potential should therefore be a combination of gut 
derived cell lines and cells from the reticulo-endothelial system (e.g. macrophages). Knowledge 
on the use of the outcome of in vitro assays and profiling studies for risk assessment needs to be 
developed further. 
o Allergenicity (or sensitization). The special role of NPs in developing food allergy needs to be 
studied. The possible adjuvant activity of NPs are amongst others a reason for serious concern. 
If a relation between food allergy and a NP is established, traceability is considered to be critical 
to anticipate and exclude possible sources for such potential allergens (Kroes et al. 2002). 
• Exposure assessment:  
o Investigate whether the default or database derived processing factors for exposure assessment 
of conventional chemical needs adaptations for NPs. 
• Other: 
o What is the feasibility of labeling of products.  
o Additional effort is needed for the education of nanoparticle/ nanotechnologies risk assessors, 
since this requires a very broad scope of expertise, which is particularly challenging given the 
rapid scientific developments in the emerging field of science.  
o How to communicate about potential risks. 
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8 Different safety issues for pre- and postmarketing nanotech products?  
The survey of products containing nanoparticles (NPs) indicated that a wide variety of products is on the 
market, especially via sales on the Internet, that likely contain nanotechnology or NPs. Part of these 
product are subjected to pre-marketing safety assessments. This means that, depending on the regulatory 
framework, a dataset of standard toxicological studies and an assessment of health risks need to be 
submitted for the application of the substance/NP in food. In a safety assessment made prior to market 
introduction of a substance it is important to address the special physicochemical features of NPs (for a 
NP as such and the NP in the food matrix), their intrinsic hazards (hazard identification), dose- 
response(effect) levels and kinetic properties (hazard characterization) and potential intake levels 
(exposure assessment). In general this results in an integrated safety assessment and the establishment of 
acceptable intake levels for humans (Risk characterization) and this can form the basis for the definition 
of necessary maximum use levels or maximum residue levels in food by risk managers (Risk 
management).  
It is clear that a wide range of products are available via internet, especially products in the category of 
the food supplements and food additives. This is a global market, where European consumers can 
purchase products directly from everywhere around the world. It can be argued that it will be very 
difficult for national authorities within the EU to strictly enforce EU regulations on this market. This 
makes it very likely that consumers can expose themselves to products of which the safety is by no 
means guaranteed. This requires a post marketing risk assessment framework to be in place.  
 
Knowledge gaps 
• Adequateness of guideline toxicological studies and risk assessment methodology. From the 
legal requirements imposed by the application of a substance (NP) in food, toxicological studies 
have to be performed and submitted to provide insight in the possible adverse effects of NP. 
Given the uncertainties identified under question 7, it cannot be concluded yet whether the study 
protocols for existing guideline toxicological studies will be able to detect all effects of NP. 
• Adequateness pre-marketing data requirements. Since it is not known whether the current 
guideline studies are adequate to detect the possible effects of NP, it is also not possible to judge 
whether the present legal data requirements are adequate (see question 7). 
• Availability of data on nanotechnologies containing products already on the market. Data 
on market penetration of NP containing food products and the consumer use of food containing 
NP is currently not at hand (see question 1 and see question 3). 
 
Research issues/ potential impact of research 
• Adequateness of guideline toxicological studies and risk assessment methodology. Make an 
more detailed overview of relevant dossier requirements, to indicate what information should 
additionally (or not) be requested for NP compared to conventional chemicals (see also question 
5). New or other legal requirements for pre-marketing safety assessment of NP for application in 
food can then be developed, guidance to producers can be provided. Adaptation of existing or 
development of new protocols for testing of toxicological effects of NPs may be a result. 
• Adequateness pre-marketing data requirements. Once more information is available on the 
dose metrics, health effects of and exposure to NP in food, the adequateness of the pre-
marketing safety research should be assessed.  
•  Availability of data on nanotechnologies containing products already on the market.. The 
development of an integrated database as identified under question 3 is important. In addition 
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monitoring of consumer use of food containing NP is relevant. High quality and reliable 
databases can be used to obtain a realistic view on products on the market and thus used for 
monitoring purposes, priority settings for post-marketing surveys and emerging risks projects. 
The post-marketing surveys should provide detailed information on the market penetration and 
type of nanotechnology applied in products. 
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9 How to come to the most efficient research approach?  
Various research agendas and roadmaps have been defined for the domain of human health and 
environmental risks of nanotechnology (OECD, (Maynard et al. 2006), EU, NNI, …). They were 
developed on the basis of various scopes, from a product point of view, from a more fundamental 
research point of view, from an economic point of view. Overall they have led to more or less the same 
research items, that are defined at a quite high level of abstraction. Moreover, a lot of these roadmaps 
were developed on a scientific or on a regulatory/policy basis. To our opinion, such roadmaps are best 
developed by an interaction of researchers, policy makers/upholders, and other stakeholders. It is 
important that all stakeholders have the same goal in mind, i.e. the development of ‘responsible’ 
nanotechnology products.  
 
Starting points:  
• While stimulating the economic developments of nanotechnologies the safety for human health 
and the environment may not be compromised. 
• Safety research should contribute to the sustainable development of nanotechnologies (used in 
the food production chain). 
• Products have already come to market, so first attention should be paid to post-marketing risks.  
• Risk assessment requirements and not fundamental toxicological issues should be leading in 
developing roadmaps for research in the most efficient way.  
 
For consideration: 
• Identify which areas for food in nanotechnology are important for the Netherlands or the EU. 
The questions raised and research topics mentioned are global issues.  
• Identify how research efforts relating to post-marketing risks should weigh in comparison to 
pre-marketing risks. 
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10 How can research issues for nanofood safety be prioritised ? 
What can be leading issues in prioritizing research items? 
At this moment already a large variety of products is at the market or is expected to reach the market 
within the near future. This implies that in the first place: 
1. research should be carried out that supports post marketing risk assessment.  
2. the current regulatory framework should be adapted in such a way that products expected in the 
near future are covered by a relevant regulatory framework. 
 
The conclusions seem to be obvious but it will still be difficult to translate this in concrete research 
proposals. The following research topics are considered to contribute pivotally to risk assessment of 
nanotechnologies and nanoparticles in general and thus also for applications in food products. 
 
• Characterization of nanoparticles. The particles have novel properties compared to conventional 
chemicals. It is important to characterize these properties to enable  realistic estimations of 
consumer exposure. But equally important, this information is needed to establish dose-response 
relations in toxicology studies. Thus, analytical tools need to be developed for the isolation and 
characterization of nanoparticles in food and biological matrices. 
• Dose metrics. This is a very basic issue which affects both interpretation of scientific studies as well 
as regulatory frameworks. It has become clear that doses of nanoparticles and thus also limit values 
for nanoparticles cannot be expressed in weight or volume measures as is the case for conventional 
chemicals. Questions arise whether nanosized particles of their conventional counterparts need their 
own limit values.  
• Effects of nanoparticles. The kinetics of nanoparticles may be different compared to conventional 
chemicals. When there is evidence for uptake, distribution of nanoparticles should be studied more 
extensively when compared to their conventional counterparts. Of special importance are those parts 
of the body that are normally protected by barriers like the blood-brain-barrier and placenta.  
• Definition of nanoparticles. This is not only a formal issue for regulators but also very important for 
discussion on prioritization of research and exchange of study results between scientists, producers 
and regulators. 
• Consumer exposure to nanoparticles. It needs to be studied which products containing nanoparticles 
are on the market and which type of particles are used, and are being developed. 
 
Specifically for applications of nanoparticles and nanotechnologies in food products are the following 
issues thought to be relevant: 
• Oral bioavailability 
• Measurement of nanoparticles in food matrices 
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Part B.  
Health impact of nanotechnologies in food production: 
Background document 
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1 Introduction  
The potential benefits of nanotechnology have been recognized by many industries, and products based 
on nanotechnology or products containing nanoparticles (NPs) are already manufactured such as in the 
field of electronics, consumer products and pharmaceutical industry. Achievements and discoveries in 
nanotechnology are beginning to impact the food associated industries (Chen et al. 2006a). 
Nanotechnology is a new and fast emerging field that involves the manufacture, processing and 
application of materials that are very small in size. Engineered NPs are commonly defined as materials 
designed and produced to have structural features with at least one dimension of 100 nanometers or less 
(Oberdorster et al. 2005a). NPs can be spherical, tubular, irregularly shaped, or can exist in fused 
aggregated or agglomerated forms. Due to novel physiochemical properties of engineered NPs that are 
attributed to their small size, chemical composition and surface structure, NPs can have novel or distinct 
(toxicological) properties (Nel et al. 2006). 
Within the food production nanotechnology tools are used in the entire food chain e.g. during cultivation 
(agriculture), industrial processing or packaging of foods. In addition nanotechnologies are being used 
to enhance the nutritional aspects of food by means of nanoscale additives and delivery systems added 
to the food. Various types of NPs can be employed within food industry ranging from inert types of NPs 
like nanofibers, metal and metal-oxides, quantum dots (Hardman 2006) and other NPs, to delivery 
systems like liposomes and other forms of nanocapsules (Taylor et al. 2005). Household use may 
include the use of nanocoated/treated containers for food storage or household appliances. 
Generally there is good appreciation of the potential benefits of nanotechnology for the food industry 
and likely the consumer. However, not too much is known on safety aspects of the application of 
nanotechnologies in food production and of the incorporation of NPs in food products. Not all 
applications and not all NPs are alike and thus they do not share the same hazard or risk profile. A 
ranking of risks given the application and type of NPs should be made, In its evaluation of potential 
health risks of products containing nanotechnology SCENIHR stated that “… The situation with free 
nanoparticles, including agglomerates, is quite different. …free nanoparticles [that] give rise to concerns 
over possible human health and environmental risks” (SCENIHR 2006). 
1.1 Aim of the project 
The aim of the project is to identify knowledge gaps in the expertise needed to make reliable risk 
assessments for human health risk in case of application of nanotechnology in food production. Based 
on this identification of knowledge gaps a priority list of research questions will be drafted, when 
resolved the answers will contribute to reduce the uncertainties in safety and risk assessments of NPs in 
food products and the use of nanotechnology in food production within a few years. This part of the 
report can be found in part A of this report. 
1.2 Outline of project 
Firstly, an overview of current (or in the near future foreseeable) applications of nanotechnology and 
NPs in food production will be provided. State-of-the-art of applications of nanotechnology within the 
following areas will be presented: 
• residues of use of nanotechnologies and NPs during production and processing 
• packaging materials 
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• food additives and nutrients 
This exploratory task mainly relies on some international inventories from the Woodrow Wilson 
International Center for Scholars and the European Nanotechnology Gateway to which information 
from a literature search will be added. 
Secondly, the safety assessment performed in the pre-marketing (authorization procedure) assessment of 
NPs or new products containing NPs will be evaluated. Specific (dossier) requirements resulting from 
the novel features of the NPs will be highlighted. However data requirements for conventional forms of 
chemicals also applicable for NPs will not be addressed. Most important knowledge gaps at each step of 
the safety assessment will be identified and accompanied by a project proposal. If executed these 
projects should increase the reliability of the safety assessment (e.g. hazard identification, hazard 
characterization, exposure assessment and risk characterization). Additionally some remarks on the post 
marketing risk assessment will be provided. 
Thirdly, a general overview with the Dutch point of view on the legal framework of nanotechnology 
application within the food area will be provided. 
Results will be used to provide the risk manager with an identification of uncertainties in the current risk 
assessments.  
The synthesis report gives an overview and an advice for priority of scientific issues that needs to be 
addressed in order to improve the process of post-marketing risk assessment for NPs in food and in 
order to gain insight in dossier requirements for NPs in food. 
1.3 Out of scope 
This project only covers health impact of application of nanotechnologies during food production and/or 
for consumers. Potential health impact of application of nanotechnologies in other industries e.g. 
electronics, medical and consumer products will not be addressed in this project. 
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2 Nanotechnology - definition and applications 
The Nobel Laureate Richard Feynman is suggested to be the first person to have the vision to see the 
potential of working at the nanoscale. In a visionary presentation in 1959 titled “There’s plenty of room 
at the bottom”, he postulated that being able to manipulate atoms and molecules at will would open up 
new avenues of technology (Feynman, 1959). Working at the atomic level became only within reach 
when key analytical tools like the scanning tunneling microscope were developed in the 1980s. 
Advances like these and other analytical tools quickly spread to be utilized in many other fields of 
science. This led to the development of materials showing unique properties that are dependent on their 
nanostructure c.q. size. Current research is leading to the development of sophisticated and 
heterogeneous materials and devices, based on an increasing ability to engineer in functionality at the 
nanoscale (Roco 2004). In his review of the development of nanotechnology Maynard emphasizes that 
the benefits that have the potential to change and improve our lives will inevitably bring with them new 
risks that need to be identified and managed (Maynard 2006).  
Nanotechnology itself and its applications are now rapidly growing, hundreds of claimed 
nanotechnology products from enhanced materials, electronic products and devices and pharmaceutical 
products are already on the market (The Nanotechnology Consumer Inventory, 2006). It is this 
broadness of application of nanotechnologies that makes it particularly difficult to discuss potential risks 
in general terms. Moreover, the broadness also makes this technology very sensitive for consumer 
anxieties, because (negative) discussions on applications nanotechnologies in one sector will have its 
effect on applications in another sector. 
As nanotechnology is an enabling converging technology used in many industries a discussion on the 
risks must start with a definition and a focus on the field of application. 
2.1 Definitions of nanotechnologies and nanoparticles 
 
Nanotechnologies are enabling and converging technologies, which means that it is not a single type of 
technology used in a single field of science, but a great variety of techniques that have only one thing in 
common: the size-scale: 
 
Nanotechnologies: The design, characterization, production and application of structures, devices and 
systems by controlling shape and size at the nanometer scale (Engineering. 2004) 
The Royal Society purposely uses the plural of nanotechnology, to express the diverse range (and 
applications) of nanotechnology.  
Other groups have included an extra criterion: it is not only the small size that matters, but also the 
added novel characteristics or properties of the new substances, products and applications that makes 
nanotechnologies a special group of technologies:  
 
Nanotechnology: The understanding and control of matter at dimensions of roughly 1 to 100 
nanometers, where unique phenomena enable novel applications (NSET, 2004) 
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Nanoscience: The study of phenomena and manipulation of materials at atomic, molecular and 
macromolecular scales, where properties differ significantly from those at a larger scale 
((Engineering. 2004) 
 
This was reworded by Maynard (2006), in his view nanotechnologies have three things in common: 
• Control – the ability to put small quantities of matter where it is wanted. 
• Utilization – using this ability for some practical purpose. 
• Visualization – detecting where material is placed and how it is configured at the nanoscale 
(Maynard 2006) 
 
The development and application of nanoparticles (NPs) is one of the results of the use of 
nanotechnologies. Besides engineered NP, nanosized particles also can have a natural origin like sand 
dust, ashes as a result of volcano eruption, or can be the unintended result of human activities. Examples 
of the latter are ultra fine particles in diesel fumes (combustion). These non-engineered particles have 
been studied extensively, especially the toxicity due to inhalation of these particles. 
 
In summary the novel (unusual) properties of engineered NP are attributable to their (Nel et al. 2006):  
 small size: resulting in a relatively large surface area (and distribution in sizes). 
 chemical composition: purity, crystallinity, electronic properties etc. 
 surface structure: surface reactivity, surface groups, inorganic or organic coatings, etc. 
 solubility, shape and aggregation. 
 
Within the food production industry it can be envisaged that engineered NPs are or will be applied in 
packaging materials, processing aids or as food additives. A different and in food area very important 
type of NPs are delivery systems like liposomes and other forms of nanocapsules (Taylor et al. 2005). 
Encapsulation will be used in novel formulations of pesticides and veterinary drugs, or to enhance the 
controlled release of food ingredients at the right place and the right time (Gouin 2004). 
 
In this document the term ‘nanoparticle’ is used as a general denominator for various types of 
engineered NPs that have at least one dimension on the nanoscale, e.g. between 1 and 100 nm, and that 
are ‘fixed’ or ‘free’: 
• Fixed: Nanoscale patterning at the surface, or nanocomposites in which NPs are permanently 
embedded into a conventional matrix structure are examples of fixed NPs. The interactions of fixed 
NPs with living systems is limited by the fact that these NPs cannot be taken up into tissues or 
individual cells. Fixed NPs can be released from their matrix (e.g. wear off, migration etc) 
• Free: Free NPs have two (nanorods, nanowires) or three of their dimensions in the nanoscale, and as 
such are small enough to be taken up into individual cells. This opens up new possibilities for 
interactions between NPs and cells, which may result in alterations in cellular signaling and cell 
function. 
Furtheron in this report with nanoparticles only the nanoparticles in its free form are discussed. 
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3 Applications of nanotechnologies in the food production chain 
Nanotechnology has the potential to impact many aspects of food and agricultural systems. 
Bioavailability, food security, disease treatment, delivery systems, new tools for molecular and cellular 
biology, new materials for pathogen detection are examples of the important items that are linked with 
nanotechnology (Weiss et al. 2006). 
3.1 Approach 
In this section an overview of products made using nanotechnology or nanoparticles (NPs) are applied is 
provided. The inventory has been made using Google™, using the search terms ‘nano’, 
‘nanotechnology’, ‘nanotubes’, ‘NPs’, ‘food’, ‘product’ in varying combinations. Most products have 
been found via the database of consumer products of the Nanotechnology project 
(www.nanotechproject.org) of the Woodrow Wilson International Center for Scholars, in the Global 
New Products Databse of Mintel (www.gnpd.com), and the Nanotechnology Product Directory 
(www.nanoshop.com) and the report of nanoforum (www.nanoforum.org). The databases and the 
internet have been searched during Spring 2007. 
3.2 Overview of applications 
The overview of the products that are claimed to be produced using nanotechnologies or containing NPs 
is provided in Annex 1. The results are summarized in Tables 3.1 and 3.2. 
The inventory clearly indicates that nanotechnologies are being used throughout all phases of food 
production (Table 3.1). It is striking that it is not one type of technologies that is being used: it ranges 
from processing techniques to the application of 'inert' or encapsulate NPs into food products.  
 
Before analyzing the results of the inventory, this search needs some critical discussion. The inventory 
is based on labeling information on the product. The claim that these products contain nanotechnology 
cannot be verified from the information presented. This also applies to the information on the presence 
and/or type of NPs applied in these products. It can be expected that the claim ‘nanotechnology’ on the 
label of some products is not more than a marketing instrument. On the other hand products containing 
nanotechnology or NPs that are not claimed on the labels are for that reason not included in this 
inventory. The results of this inventory are thus clearly biased.  
 
Types of application 
The most striking observation is that nanotechnologies are being used throughout all phases of food 
production (Table 3.1). It is clear that it is not one type of technologies that is being used: it ranges from 
nanoformulated agricultural compounds (e.g. pesticides), to processing techniques and the addition of 
inert or encapsulate NPs into food products. The type of application can be used as a first estimate of 
potential consumer exposure and thus as a ranking of risks. Nanotechnology used for the food 
production without introducing (e.g. adding) nanoscale products or compounds in the food like filters 
with nanopores, can be considered of low risk for the consumer. The use hand-held devices containing 
nanotechnology or filters with nanopores to create monodisperse solutions or to filter out 
microbiological contamination are examples of this category of applications.  
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Direct (intentional) application of NPs in food can start early in the food chain when nanoformulations 
of pesticides are applied directly on crops. The other potential source might origin from residues of NPs 
for water and soil cleaning purposes in fields on which crops are cultured, could become available for 
the consumer. Or by contamination with NPS as a result of environmental release of NPs from 
production processes. 
In addition, the application of 'sensor sprays' to conventional materials to monitor contamination with 
micro-organisms is a direct source for NPs in food when products from the surface are consumed. While 
filters with nanopores (and therefore using nanotechnology) become in direct contact with food this 
application of nanotechnology is expected to have no additional safety concerns in comparison with 
conventional filters. The type of material (and wear-off as result of use) of the filters or cleaning 
products of the filters might require some attention, but this is clearly not exclusively related to safety of 
nanotechnology.  
The ultimate direct consumer expose can be expected when NPs are included into food directly (with an 
e.g. antimicrobial-, enhancing bioavailability- or targeted delivery function).  
Indirect application of NPs in food can be expected when nanotechnological devices are incorporated in 
packaging materials, storage containers of food preparation equipment. In packaging materials two 
types NP can be identified. Inert particles to increase barrier or strength properties of the packaging 
materials and (re)active particles. The latter are designed to respond to environmental changes (e.g. 
temperature in storage rooms), degradation products of the food commodities, or contamination by 
micro-organisms. NPs used in these applications can migrate or wear-off from the materials before 
consumers exposure can be expected.  
 
Inert particles are used in the food production chain (Table 3.2) with a diverse aimed function. Examples 
are aluminum oxide, lanthanum particles and nanoscale iron powder in the process of water purification/ 
soil cleaning. In food storage and processing, silver and zink oxide NPs are handled in refrigerators and 
storage containers. Silicate NPs, nanocomposite and magnesium - and zink oxide are used in food 
packaging materials, while also inert particles are processed in food commodities, like calcium, 
magnesium, silver, silicate, silicium oxide and white gold. Other applications in food commodities are 
nanosized particles, regulatory peptides from plants, nanodroplets/- clusters and nanowater. However, 
the form of abovementioned particles is usually unknown. Consumer exposure can be expected 
following application of inert particles in the food, while expected consumer exposure is low as long as 
NPS remain bound in the packaging materials or in the coating on surfaces of packaging materials and 
food preparation devices (risk of wea-off). There, crucial safety related issues are migration of these in 
to food and appearance (e.g. free or as large aggregates) of these NPS in the food. As stated before, it 
are the free forms of the NPS that are reason for safety concern (SCENIHR 2006). 
The other type of NPS that are encountered are the nanodelivery systems, of which a diversity of forms 
exist (Letchford and Burt 2007; Taylor et al. 2005). When incorporated into food the delivery systems 
are commonly build from peptide or lipid monomers (Chen et al. 2006b; Graveland-Bikker and de Kruif 
2006; Mozafari et al. 2006). These Nanoencapsules are used for novel pesticide formulations, 
consumers exposure to residues of these particles can thus be expected. The other major application of 
encapsulates are the use of delivery system for bioactive compounds, e.g. to increase the bioavailability 
of these compounds.  
 
 RIKILT /RIVM Report 2007.014 36 
While potential consumer exposure might be a useful approach to ranking potential risks of 
nanotechnology, this could also be approached from a regulatory side. Which applications are likely 
adequately subjected to a regulatory framework and what is the likelihood of enforcement? All 
compounds that are to be used in food or expected to be used in products in contact with food are 
subject to pre marketing authorization procedures. Most import regulatory frameworks for the 
authorization of compounds to be used in food are the following: 
• The European General Food Regulation (EC/178/2002) 
• Novel food [and novel food ingredients] Regulation (EC/258/97) 
• Food additives, enzymes, flavourings and processing aids (89/107/EC; 94/36/EC; 94/35/EC; 
95/2/EC and their amendments). 
• Food enrichments regulation (EC/1925/EC) 
• Food supplements directive (2002/46/EC) 
• Food contact materials (EC/1935/2004) 
• And regulations and directives on pesticides and veterinary drugs. 
In general terms these regulations have safety provisions incorporated. It is the producer’s responsibility 
that their products are safe. Regulatory agencies assess the dossiers that are submitted by applicants. 
The adequacy of the safety provisions and testing will be elaborated on in the following sections. 
However, it is also clear that a wide range of products, especially the food supplements and food 
additives, are available via internet.. While all products on the (internet) market in principle are 
subjected to the above indicated regulatory framework it can be argued that it will be very difficult for 
national authorities to strictly enforce this market. This will necessitate a post marketing risk assessment 
framework to be in place.  
 
Table 3.1 Summary of applications of nanotechnology in the food production chain 
Chain phase Application Nanotechnology Function 
Agricultural 
production 
Nanosensors Nanospray on food commodities Binds and colors micro organisms 
  Hand-held devices Detection of contaminants etc. 
  Incorporated in packaging materials Detection of food deterioration. 
 Pesticides Nanoemulsions, -encapsulates Increased efficacy, water solubility and 
crop adherence 
  Triggered release nanoencapsulates Triggered (local) release 
 Water purification/ 
soil cleaning 
Filters with nanopores Pathogen/ contaminant removal 
  NPs Removal or catalysation of oxidation of 
contaminants 
Production and 
processing of 
food 
Food production Nanoceramic devices Large reactive surface area 
 Refrigerators, 
storage containers, 
food preparation 
equipment 
Incorporated nanosized particles, 
mostly silver, occasionally zinc 
oxide 
Anti-bacterial coating of storage and 
food handling devices 
Conservation Food products Nanosized silver sprays Anti-bacterial action 
 Packaging 
materials 
Incorporated sensors Detection of food deterioration. 
Monitoring storage conditions 
  Incorporated NPs Increasing barrier properties, strength of 
materials 
  Incorporated active NPs Oxygen scavenging, prevention of 
growth of pathogens 
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Chain phase Application Nanotechnology Function 
’Functional 
food’, 
consumption 
Supplements  Colloidal metal NPs Claimed to enhanced desirable uptake 
  Delivery systems "Nanoclusters" Protecting and (targeted) delivery of 
content 
    
  Nanosized/-clustered food/drinks 
(nutrients) 
Claimed enhanced uptake 
    
 
Table 3.2 Summary of type of NPs and NPs applied in the food production chain 
Type of NP Application Function 
Colloidal metal NPs Food additive Claimed to enhance desirable GI-uptake  
Metal NPs (Silver, ZnO) Food additive/supplement Claimed enhanced uptake 
 Packaging materials/ storage Increase barrier properties 
 Food preparation devices Clean surface 
 Refrigerators, storage containers Anti-bacterial coating of storage and food handling 
devices 
 Water purification/ soil cleaning Removal or catalysation of oxidation of contaminants 
 Sprays Anti-bacterial 
Nanosized nutrients /foods Food additive /supllement Claimed enhanced uptake 
Complex nanoscale 
structures 
Nanosensors in packaging Detection of food deterioration. 
Monitoring storage conditions 
 Hand-held devices Detection of contaminants etc. 
Incorporated active NPs (migration out of) packaging 
materials 
Oxygen scavenging, prevention of growth of 
pathogens 
Filters with nanopores Water purification Removal pathogens, contaminants 
 Equal emulsions Product design 
Delivery systems 
(nanoencapsulates) 
Food additive / supplement 
 
Protecting and (targeted) delivery of content 
 Pesticide Increased efficacy, water solubility and crop 
adherence, triggered (local) release 
3.3 Description of types of nanoparticles 
3.3.1 Inert particles 
A NP consists of a solid or liquid nanostructure present in the air as an aerosol (mostly solid or liquid 
phase in the air), a suspension (mostly solid in liquids) or an emulsion (two liquid phases). Different 
characteristics of NPs are:  
• particle size 
• surface area per unit mass 
• shape 
• solubility and dissolution 
• reactivity 
• coagulation or aggregation state 
• chemical composition 
• other 
 
As can be seen also from Table 3.3, NPs can be spherical, tubular, irregularly (non-spherical) shaped, or 
can exist in fused aggregated or agglomerated forms. 
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Table 3.3 Different types of nanostructured particles 
Particle Type Description 
 
Spherical or compact particles  
Compositionally homogeneous 
 
High aspect ratio particles  
Compositionally homogeneous 
 
Complex non-spherical particles  
Compositionally homogeneous 
 
Compositionally heterogeneous particles  
Core-surface compositional variation 
 
Compositionally heterogeneous particles Distributed 
compositional variation 
 
Homogeneous agglomerates  
Agglomerates of a single particle class 
 
Heterogeneous aggregates  
Aggregates of diverse particle types 
 
Active particles  
Particle behavior and properties depend on external 
stimuli 
 
Multifunctional particles  
Particle behavior and properties depend on functional 
responses to local environment and stimuli 
 
These characteristics are important with respect to potential risks for health or environment and 
determine their fate and behavior in the environment, humans and other organisms.  
3.3.2 Encapsulates 
Nanoencapsulation involves the incorporation, absorption or dispersion of bioactive compounds in/at or 
on small vesicles with nano (or submicron) diameters that may protect the bioactive compounds against 
degradation, improve the stability and solubility of the substance and therefore increase the 
bioavailability and delivery to cells and tissues (Letchford and Burt 2007; Taylor et al. 2005). Reducing 
the size of the encapsulates into the nanoscale offers opportunities related to prolonged gastrointestinal 
retention time caused by bio-adhesive improvements in the mucus covering the intestinal epithelium 
(Chen et al. 2006b; Medina et al. 2007). Modulations of surface properties (e.g. coatings or 
biomolecular flags) can enable targeted delivery of compounds. The latter field of application is typical 
of biomedical application of encapsulates. 
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Nanoencapsulates may consist of a core composed of one to several types of compounds surrounded by 
a wall or barrier (see fig 3.1. for types of delivery systems relevant for food industry). These delivery 
systems have its roots in the pharmaceutical industry where often synthetic polymeric nanoencapsulates 
are employed. For application of nanoencapsulates into food, lipid- or natural polymers-based capsules 
are most often applied or studied (Chen et al. 2006b). However, one of the main problems with these 
natural polymers is the stability of the nanoencapsulates. 
 
Figure 3.1 Classification of nanoparticulate delivery systems.  
 
Lipid-based nanoencapsulation: 
The main lipid-based nanoencapsulation systems that can be used in food and food supplements are 
nanoliposomes, archaeosomes and nanocochleates (Mozafari et al. 2006).  
- Nanoliposomes are defined as bilayer lipid vesicles possessing and maintaining nanometric size ranges 
during storage and application. Because of their unique properties they can entrap, deliver and release 
both water-soluble and lipid-soluble material (Mozafari et al. 2006). Liposomes may release their 
contents into cells upon e.g. encountering specific cellular enzymes, due to pH or thermo-sensitivity or 
after antigen-binding when antibody-tagged (Taylor et al. 2005). 
- Archaeosomes, which are liposomes made from Archaeobacteria, are even more thermostable and 
more resistant to oxidation, low pH, bile salts, chemical and enzymatic hydrolysis compared with 
normal liposomes and therefore considered ideal candidates to protect antioxidants during food 
processing.  
- Nanocochleates have a cigar-shaped multilayered structure consisting of a continuous, solid, lipid 
layer sheet rolled up in a spiral fashion with little or no internal aqueous space. Nanocochleates have 
been used to deliver proteins, peptides and DNA for vaccine and gene therapy applications. They are 
resistant to degradation in the gastrointestinal tract, which makes them ideal candidates for oral delivery. 
 RIKILT /RIVM Report 2007.014 40 
Because of the natural composition of liposomes it may appear that there are no safety concerns if 
liposomes are used in food industry. However, as was pointed out by Mozafari et al. (Mozafari et al. 
2006), the utilization of above mentioned lipid-based carriers in the area of food is determined by their 
preparation procedure, which may not involve non-food grade solvents and detergents.  
 
Polymer-based nanoencapsulation: 
Nanoencapsulates based on polymers can be obtained by the polymerization of more than one type of 
monomer, typically one hydrophobic and one hydrophilic, so that the resulting molecule is composed of 
regions that have opposite affinities for an aqueous solvent. Numerous copolymers have been 
synthesized to date, generally composed of a biocompatible, biodegradable hydrophobic polymer block 
covalently bounded to a biocompatible hydrophilic polymer block, leading to the formation of micelles, 
nanospheres, polymersomes and nanocapsules (Kabanov 2006; Letchford and Burt 2007). In figure 3.2 
the delivery systems formed by amphiphilic copolymers are shown.  
- Micelles are characterized by a core-shell architecture in which the inner core is composed of the 
hydrophobic regions of the amphiphilic molecules creating a cargo space for the lipophilic drug or 
compound.  
- Nanospheres can be defined as a solid colloidal particle in which drugs are dissolved, entrapped, 
encapsulated, chemically bound or adsorbed to the polymer matrix. However, the central core can be 
become more or less solid-like depending on the copolymer composition, making if difficult to have a 
clear distinction between micelles and nanospheres.  
- Nanocapsules and polymersomes are colloidal-sized, vesicular systems in which the drug is confined 
within a cavity surrounded by a polymer membrane or coating. If the core is an oily liquid and the 
surrounding polymer a single layer the vesicle is referred as a nanocapsule; these system have found 
utility in delivery of hydrophobic compound. If the core of the vesicle is an aqueous phase and the 
surrounding coating is a polymer bilayer, the particle is referred to as a polymersome. These vesicles are 
analogous to liposomes and find utility in delivery of encapsulation of water-soluble compound, but 
they differ from liposomes in that the external bilayer is composed of amphiphilic copolymers. Variation 
in composition, molecular geometry and relative monomer lengths results in various physicochemical 
properties and morphologies of the resulting nanoencapsulates (Letchford and Burt 2007). 
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Figure 3.2: Nanoparticulate drug delivery systems formed by amphiphilic copolymers and their general 
characteristics. Taken from (Letchford and Burt 2007). 
 
In food industry food-grade polymers have to be utilized. For instance, polyethylene glycol (PEG) is 
generally used as a hydrophilic polymer block in the formation of nanoencapsulates (Letchford and 
Burt, 2007) and generally recognized as safe. Moreover, protein-based nanoencapsulates are particularly 
interesting because they are relatively easy to prepare and can form complexes with polysaccharides, 
lipids or other biopolymers and a wide variety of nutrients can be incorporated (Chen et al. 2006b). 
Natural polymers used for the formulation of nano delivery systems are albumin (protein), gelatin 
(protein), alginate (saccharide), collagen (protein), chitosan (saccharide) (des Rieux et al. 2006) and the 
milk protein alpha-lactalbumin (Graveland-Bikker and de Kruif 2006). 
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4  Scientific data for risk assessment of nanoparticles in food 
4.1 Physicochemical characterization of nanoparticles, stability in the food 
matrix and availability of analytical tools 
Engineered nanoparticles (NPs) encompass many forms. They can be made bottom up, through 
assembling molecules into NPs, or derived top down by down sizing conventional substances. A 
complete and accurate characterization of NPs (Oberdorster et al. 2005a; Powers et al. 2006) is an 
essential part of both understanding the possible benefits as well as the potential toxicity of NPs in 
biological systems (Royal Society, 2004). Whereas the characterization of chemicals is usually 
relatively straightforward (e.g. composition, purity), characterization of NPs in biological matrices is 
more complex (Powers et al. 2007). The novel properties of NPs are primarily associated with their 
small size.  
There is a commonly used definition which states: 
 
“Engineered NPs materials are designed and produced to have structural features with at least 
one dimension of 100 nanometers or less (Oberdorster et al. 2005a)” 
 
Nanotechnology involves the manufacture, processing and application of materials that are in the size 
range of 100 nanometers or less. The size limits have once been chosen on an the basis of physico-
chemically relevant properties, but have however no toxicological basis at all.  
In international fora like Scientific Committee on Emerging and Newly-Identified Health Risks 
(SCENIHR) and the International Organization for Standardization (ISO) discussions on definition are 
high on the agendas. International consensus on a definition will have its impact on regulatory 
frameworks. At this moment discussions seem to lead in the direction of defining the upper size limit of 
a NP is as approximately 100 nm, which is not strict enough for application in regulatory frameworks. 
It is however important to realize that the size may not be the only relevant descriptor of a dose of NPs 
e.g to explain these novel properties of NPs. Other characteristics that need to be considered are (Muller 
et al. 2001; Oberdorster et al. 2005a; Powers et al. 2006):  
 size and size distribution,  
 agglomeration state 
 shape and other morphological features (e.g. crystallinity, porosity, and surface roughness),  
 chemical composition,  
 solubility,  
 total surface area,  
 surface chemistry  
 surface charge (zeta potential) 
Toxicity testing of NPs requires that in the end dose-respons relationships can be described, either for    
in vivo or in vitro tests. As already mentioned above, the conventional approach on the basis of mass in 
describing the dose of a compound will not hold (SCENIHR Opinion, 2007). However up till now it has 
not been possible to establish a single alternative dose-describing parameter that describes the dose and 
the observed dose response relations in toxicological tests well. This leads to a general recommendation 
that NPs used for (toxicological) studies should be characterized as completely as possible (Oberdorster 
et al. 2005a) (Powers et al. 2006) (Thomas and Sayre 2005).  
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This leads to a general recommendation that NPs used for (toxicological) studies should be 
characterized as completely as possible (Oberdorster et al. 2005a; Powers et al. 2006; Thomas and Sayre 
2005). For a comparison of studies and determining the accuracy of the methods used in different 
laboratories, it is important to assess the precision of analytical (screening) methods, lab-to-lab variation 
and effects of method development (Kroes et al. 2002). This is not only important for the safety 
evaluation but it is also important to be able to model NP properties in silico in the future (e.g. QSAR) 
(Powers et al. 2007). 
It might however not be possible to fully characterize the NPs. In an attempt to give some guidance on 
prioritization of characterization of NPs Oberdörster and coworkers (Oberdorster et al. 2005a) proposed 
three criteria: "the context within which a material is being evaluated, the importance of measuring a 
specific parameter within that context, and the feasibility of measuring the parameter within a specific 
context". Part of this information is currently presented in the relevant dossier parts, but it is clear that 
more information should be requested. 
Physicochemical characterization of NPs is important to be able to explain observed effects in test 
systems. Characterization of NP as-produced will provide useful baseline data of the NPs. But for 
toxicity studies and (consumer) exposure assessment, it is crucial that this characterization is performed 
in the matrix containing the NPs as administered to test systems (or consumer) (Oberdorster et al. 
2005a). It is clear that the functionalities of the NPs (e.g. particle size, size distribution, potential 
agglomeration and surface charge), can change in different biological matrices (Powers et al. 2006), 
depending on compounds that are present in the matrix and thermodynamic conditions (Borm and 
Kreyling 2004). In addition NP interactions with the matrix can change as a result of dilution 
(Oberdorster et al. 2005a). In practice this means that the appearance of a NP can be expected to change 
following  sample processing (e.g. freeze - thaw cycles, heating, dilution). A special case is NP 
incorporation in packaging materials. The rate of migration of NPs from packaging materials is not 
known a priori. The migration of heavy metals from biodegradable starch/clay nanocomposite films to 
be used as packaging materials, was shown to be minimal (Avella et al. 2005). It is not clear however 
whether the results from this study are applicable in general. Furthermore the adequacy of current 
migration tests and cut off migration limits need to be considered. And for a thorough safety evaluation 
the NPs will also have to be characterized after migration into the food matrix. 
 
At present there is a vast array of analytical techniques to characterize NPs. The mean size and width of 
distribution (polydispersity index) of nanosuspensions is typically determined by photon correlation 
spectroscopy (PCS). The measurement range of this technique is limited to approximately 3 nm-3um. 
Therefore, additional laser diffractometry (LD) with a measuring range of approximately 0.05 –80 um is 
used to detect any presence of particles in the micrometer range or aggregates of NPs (Muller et al. 
2001). Analysis by the Coulter counter technique gives absolute data (i.e. absolute number of particles 
per volume unit for the different size classes). 
Other methods to determine the size distribution of NPs are light scattering, differential mobility 
analysis, time of flight mass spectroscopy (TOF-MS), microscopy and surface area measurements 
(Powers et al. 2006).  
Particle charge is generally measured by electrophoresis and typically expressed as electrophoretic 
mobility [(um/S)/(V/cm)] or converted to the zeta potential (mV) (Muller et al. 2001; Powers et al. 
2006).  
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The crystalline structure of a nanosuspension can be assessed by differential scanning calorimetry 
(DSC) (Muller et al. 2001) polarized optical microscopy and scanning electron microscopy (Avella et al. 
2005). 
For determining hydrophilicity/ hydrophobicity (important characteristic affecting the in vivo organ 
distribution (after i.v. injection) can be determined with hydrophobic interaction chromatography (HIC) 
(Luck et al. 1997). 
NPs are often coated with proteins in order to modify the surface characteristics (e.g. to increase 
adhesion to the gut wall, (Muller et al. 2001)).Qualitative and quantitative composition of protein 
absorption patterns can be analyzed by 2-D PAGE. Molecular composition and structure of the surface 
of NPs can be determined by electron spectroscopy for chemical analysis (ESCA), X-ray photoelectron 
spectroscopy (XPS) and secondary ion mass spectroscopy (SIMS), or a technique called matrix assisted 
laser desorption ionization microscopy/mycroscopy (Powers et al. 2006). 
For inert NPs the surface area is important, because interaction between NPs and the biological matrix 
typically take place at the particle’s surface. Surface area of these type of NPs is normally measured 
through gas adsorption using the Braunauer, Emmett and Teller (BET) method or other theoretical 
approaches. These measurements are difficult in biological matrices (Powers et al. 2006). 
In general, all these techniques require a well equipped laboratory and were developed for 
characterization of NPs during the production phase (in simple matrices), water (buffer) or in the air. 
Literature on validated methods for the characterization of NPs in biological or food matrices is scarce. 
4.1.1 In vitro testing 
The development of routine analytical techniques for the characterization of NPs might be very difficult 
to achieve. A completely different approach can be the determination of the presence of NPs by means 
of effect screening in analogy with screening approaches used for complex mixtures of chemicals and 
products derived from genetically modified organisms in food. In this approach the presence of NPs can 
be “detected” focusing on biomarkers of exposure or effect of developed assay systems. The in vitro 
assays could then be used in a first tier of detection of NPs in food. However, suspected samples whould 
have to be further characterized by means of analytical techniques. 
4.1.2 Summary / interpretation physicochemical characterization 
Complete information on relevant physicochemical properties of engineered NPs is considered to be 
essential for proper risk assessment. This information is required for development and confirmation of 
theoretical approaches of dose metrics. First then it will be possible to evaluate and compare the results 
of toxicity studies in a proper way.  
The size limit in the present definition of NPs is still arbitrary due to lack of knowledge on the 
relationship between particle size, kinetics and effects. It is thus not known whether the size-range of 
interest is exactly at 100 nm or below or above. Otherwise, it will be relevant to explore the legal 
feasibility of avoiding arbitrary size limits, in order to handle the consequences of scientific 
uncertainties in a more pragmatic way. Such knowledge is not easily derived. The definition should 
therefore first be treated in a pragmatic way.  
It has become clear that the size will not be the only descriptor of a dose e.g not be the only factor to 
explain these novel properties. Total surface area or number of particles are also considered to be 
relevant descriptors. In practice NPs in food will cover a certain range of sizes (distribution) and the 
particles will have a variety of shapes. These two issues already imply that doses cannot be described on 
a weight or volume basis, but it is also to simple to assume that a one dimensional parameter like 
surface area can be a good substitute.Probably, multifactorial units, taking into account all relevant 
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parameters will need to be developed. .As stated above, it will be challenging to combine these 
parameters to one relevant dose descriptor. 
Dose response relations in toxicity tests will have to be analyzed case by case using different dose-
describing parameters. Furthermore, since the functionalities of the NPs (e.g. particle size, size 
distribution, potential agglomeration and surface charge), can change in different biological matrices, or 
as a result of dilution, it is crucial for toxicity studies and (consumer) exposure assessment that the 
physicochemical characterization is performed in the matrix containing the NPs as administered to test 
systems (or consumers) (Oberdorster et al. 2005a).  
Regarding the present knowledge on toxicity of NPs it  is important for risk assessors to have access to a 
clear description of the analytical methods that were used to determine the physicochemical properties 
of the respective NP, to have access to the (raw) experimental data and a sound description of the 
statistical procedure used to analyze the data. Only then a reliable assessment of the NPs can be 
performed and only then the results of the safety assessment can be used to model NP properties in 
silico (Powers et al. 2007), or compare results with those of non-nano counterparts. 
Future research should focus on methods that are able of in situ detection and characterization of NPs, 
and that are preferably relatively easily performed with apparatuses that are currently present at 
laboratories suited for detection of chemicals in food. Ideally, isolation and characterization methods 
should be developed, suitable for routine and low-cost analysis. 
The use of in vitro effect assays might be considered as the first tier for gaining insight in potential 
presence and toxicity of NPs in certain products. In this approach the presence of NPs can be “detected” 
focusing on biomarkers of exposure or effect of developed test systems. Their application might be less 
time-consuming and expensive on one hand, but on the other hand the results of these types of assays 
are only to be used in a qualitative or semi-quantitative way.   
 
Several international working groups, like ISO and the EU Scientific Committee on Emerging and 
Newly Identified Health Risks (SCENIHR) are considering definitions of nanotechnologies and NPs 
that both adequately describe the novel nature of NPs and are applicable in regulatory frameworks. A 
generally accepted definition of NPs is essential for all stakeholders, i.e. regulators, producers and 
researchers. 
Knowledge on dose-describing parameters will be important imput for these discussions. A proper dose 
metrics will help researchers to compare study results and will help regulators to formulate limit values. 
It will also enable risk assessors to compare and combine exposure and hazard information and 
conclude on the likelihood of health risks. 
4.2 Toxicokinetics of nanoparticles 
The potential toxicity of NPs is determined by their toxicokinetic (Figure 4.1) and toxicodynamic 
behaviour, i.e. the absorption (uptake), metabolism (biotransformation), distribution (allocation) and 
excretion (elimination) characteristics in combination with the interaction of the substance with target 
sites and the subsequent reactions leading to adverse effects. Since NPs show remarkable structural 
diversity (such as tubes, dots, wires, fibres and capsules) with each structure exhibiting its own 
individual characteristics (Ballou et al. 2004; Roszek et al. 2005; Singh et al. 2006) it is reasonable to 
assume that these deviations in properties may lead to different toxicokinetic and toxicodynamic effects. 
When compared to their macrosized counterparts, all nanoscale materials have physical, chemical, 
optical, electrical, catalytical and mechanical properties that may differ fundamentally leading to a 
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different distribution pattern (Preining 1998). Furthermore, the relative large surface area compared to 
the volume of NPs can make them more reactive than larger particles, which may increase the potential 
toxicity. Although scientific knowledge on the potential toxicity of NPs is limited, several studies 
suggest that NPs may have a different toxicity profile when compared to their larger counterparts 
(Donaldson et al. 2001; Oberdorster et al. 2005a).  
Analysis of the available literature of toxicokinetics of NPs of various nature and type (in drugs, food, 
non-food products) demonstrated that no general conclusions on Absorption, Distribution, Metabolism 
and Excretion (ADME) for NPs can be drawn. As stated before, study results from various studies can 
hardly be compared due to a lack of proper dose metrics and characterization of the NPs applied in the 
studies. No coherent set of studies regarding certain types of NPs appeared even to be available. 
 
 
Figure 4.1: The ADME processes (absorption, distribution, metabolism and excretion) of NPs in the 
human body. The internal exposure is the part of the external dose that reaches the systemic circulation. 
The black lines represent confirmed routes for NPs; the dashed lines represent hypothetical routes. The 
transport rates and retention times for the indicated processes are largely unknown. (Other organs are: 
e.g. spleen, heart, reproductive organs. Modified from (Oberdorster et al. 2005b). 
4.2.1 Absorption 
Following oral uptake, NPs as well as nanoencapsulates have to pass the gastrointestinal epithelium 
before they enter the liver and subsequently the systemic circulation. This epithelium primarily consists 
of enterocytes, representing the majority of the cells, goblet cells and M-cells. The latter are localized in 
the Peyer’s Patches. In theory, particles can cross the epithelium by two main routes: paracellular 
(between the cells, through the tight junctions) and transcellular (through the cells). The rate of particle 
uptake via one of abovementioned routes is depending on the properties of the nanoparticle or 
nanoencapsulate (e.g. size, hydrophobicity, surface charge or surface coating).  
The first uptake route of nanoparticals or nano-encapsulates is the paracellular route (Figure 4.2). The 
total area of the paracellular route has been reported to range from 0.01% (Pappenheimer and Reiss, 
1987 in (Salamat-Miller and Johnston)) to 0.1% (Nellans, 1991 in (Salamat-Miller and Johnston), 
corresponding to a surface area of 200 to 2000 cm2 (Salamat-Miller and Johnston 2005). Cells of the 
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gastrointestinal epithelium are tightly connected to each other by means of tight junctions. However 
there is body of evidence that is indicating that the intestinal epithelium is permeable to large proteins 
and polypetides (Salamat-Miller and Johnston 2005). It has become clear that the permeability of the 
tight junctions can be modulated; some polymers can act as expanders of the tight junctions thereby 
introducing a port of entry for many particles as well as an entrance for toxins, bacteria and 
immunogens (Salamat-Miller and Johnston 2005). Moreover, it is not fully known whether these effects 
are reversible and hence if the opening of the cellular barrier is transient (Salamat-Miller and Johnston 
2005). 
The other uptake route is the transcellular route and describes the process by which particles are taken 
up at the apical side of the intestinal epithilium by endocytocis, transported through the entrocytes and 
subsequently released at the basolateral side of the intestinal epithilium. It is generally acknowledged 
that nanoparticle (50nm – 20 µm) translocation primarily occurs in the Peyer's Patches via the M-cells 
and to a lesser extent via the enterocytes. There is however evidence that the particle uptake and 
transportation via enterocytes cannot be neglected (Aprahamian et al. 1987; Carr et al. 1996; des Rieux 
et al. 2006; Florence 2005; Hillery et al. 1994; Hoet et al. 2004; Jani et al. 1990)(Figure 4.2), coating of 
the nanoparticle with e.g. lectins will stimulate enterocytes to endocytose the NP (Russell-Jones et al. 
1999). 
Initially it was assumed that the Peyer’s Patches did not discriminate strongly in the type and size of the 
absorbed particles. Later it has been shown that modified characteristics, such as particle size, the 
surface charge of particles, attachment of ligands or coating with surfactants, influences the uptake of 
particles by the gastrointestinal tract (Hoet et al. 2004). Small polystyrene NPs appeared to be more 
easily absorbed compared to larger particles (Desai et al. 1996; Jani et al. 1990). In addition, charged 
particles exhibited poor oral bioavailability through electrostatic repulsion and mucus entrapment 
compared to non-ionic hydrophobic particles(Florence 1997; Florence 2005; Hoet et al. 2004; Hussain 
et al. 2001).  
Specific for the M-cells is the transepithelial vesicular transport with little or none of the endocytosed 
material directed to lysosomes. It is not clear to what extent endocytosed materials are degraded or 
processed during transepithelial transport (Kraehenbuhl and Neutra 2000). Endocytosed intact 
encapsulates or NPs might thus enter both the blood and lymphoid circulation (Gabor et al. 2004)A 
special aspect of nanoencapsulates is their interaction with membranes of epithelial cells. For instance 
(synthetic) polymers have been shown to interact with charged groups of membrane proteins. That may 
affect cell signaling processes involved in inflammation, differentiation, proliferation and apoptosis, 
interfering with normal cell function (Kabanov 2006). Moreover, synthetic polycationic polymers 
caused nanoscale hole formation in lipid bilayers allowing the diffusion of molecules in and out. At 
higher concentrations the polymers even caused substantial membrane damage resulting in cell death 
(Hong et al. 2006). 
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Figure 4.2: Transport mechanisms for NPs (Modified from (des Rieux et al. 2006)). 1 = Passive 
diffusion, 2 = Paracellular transport, 3 = Trancytosis by M-Cells, and 4 = Transcytosis by enterocytes. 
4.2.2 Distribution 
After the absorption process of NPs by the various ports of entry, the systemic circulation can distribute 
them towards all organs and tissues in the body (Figure 4.1). Several studies have shown distribution of 
of NPs (including C60 fullerenes,  99mTechnetium-labeled carbon NP, 192Iridium NP, 13Carbon NP and 
colloidal gold NP)   to a variety of target organs including liver, spleen, kidneys, bone marrow, lungs 
and brain (Borm et al. 2006; Hillyer and Albrecht 2001; Ji et al. 2006; Nemmar et al. 2002; Oberdorster 
and Utell 2002).  
4.2.2.1 Distribution following oral exposure 
Oral uptake (gavage) of polystyrene spheres of different sizes (50 nm to 3 micron) in female Sprague 
Dawley rats resulted in a size dependent systemic distribution of the NPs. About 7% (50 nm) and 4% 
(100 nm), was found in the liver, spleen, blood and bone marrow. Particles larger than 100 nm did not 
reach the bone marrow and those larger than 300 nm were absent from blood. No particles were 
detected in heart or lung tissue (Hoet et al. 2004; Jani et al. 1990). 
Hillyer and Albrecht showed that after oral administration of metallic colloidal gold NPs of decreasing 
size (58, 28, 10 and 4 nm) to mice an increased distribution to other organs was observed. The smallest 
particle (4 nm) administered orally resulted in an increased presence of gold particles in kidney, liver, 
spleen, lungs and even the brain. The biggest particle (58 nm) tested was detected almost solely inside 
the gastrointestinal tract (Hillyer and Albrecht 2001). As to be expected, this suggests that both the 
absorption and distribution of this type of NPs is size dependent (Hillyer and Albrecht 2001; Jani et al. 
1990). 
3 2 1 
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4.2.2.2 Systemic circulation 
When NPs or nano-encapsulates reach the systemic circulation, the particles can, potentially, interact 
with plasma-proteins, coagulation factors, platelets and red and white blood cells. This interaction is 
depended on the surface chemistry of the particle as is shown by Nemmar et al. (Nemmar et al. 2002).  
In this study, carboxylate-polysterene, amine-polysterene and unmodified polystyrene (60nm) particles 
revealed distinct tendency to induce thrombis formation after intravenous and intratracheal 
administration in hamsters. In addition, the binding of NPs to plasma components may have a 
substantial effect on their distribution and excretion. For instance, the hydrophobic surfaces of 
nanospheres are highly susceptible to opsonization and clearance by the reticuloendothelial system, 
resulting in sequestering of the particles within organs such as the liver and spleen (Letchford and Burt 
2007). 
Several different NPs (gold and titanium oxide) have been identified inside human red blood cells 
(Rothen-Rutishauser et al. 2006) Interestingly, this cellular uptake of NPs did not involve endocytosis or 
phagocytosis (Geiser et al. 2005) since erythrocytes do not have phagocytotic receptors (Rothen-
Rutishauser et al. 2006). This suggests that NPs are able to cross the cell membrane by processes other 
than phagocytosis and endocytosis. Diffusion, transmembrane channels, adhesive interactions or other, 
undefined, transmembrane processes might play an important role in this cellular uptake. The 
intracellular NPs of this type appeared to be  not membrane bound and might have direct access to the 
intracellular proteins, organelles and DNA of the cell, which might imply enhanced toxic potential 
(Geiser et al. 2005). 
Depending on the physico-chemical properties of the nanoencapsulates, they can be internalized and 
release their content in the cytoplasma or remain intact for cellular uptake. Poly (D,L-lactide-
coglycolide) NPs showed efficient endocytosis (Panyam and Labhasetwar 2003). In addition, 
nanoencapsulates in lipsomes can also enter the cell by fusion of the liposome with the cell membrane 
(Ulrich 2002). It needs to be further explored what the effect of encapsulates including compounds is on 
membrane integrity and cell function. 
4.2.2.3 Trans-placental distribution 
Data addressing the distribution of NPs to the reproductive cells is, as yet, unavailable. In addition, no 
clear data is available identifying the distribution of NPs in the fetus. An in vivo study in which 
pregnant mice were intraperitoneally injected with soluble C60 fullerenes indicated transfer into the 
embryo via trans-placental passage of the maternal blood flow (Tsuchiya et al. 1996). However, a direct 
passage from the peritoneal cavity into the uterus could not be excluded.. Nevertheless, reproductive 
toxicity, including excretion via breast milk, needs serious attention as this is an important issue for risk 
assessment. 
4.2.2.4 Distribution to the brain 
NPs may enter the brain by two different mechanisms. The first process involves a transsynaptic 
transport of NPs through the olfactory epithelium (Elder et al. 2006; Oberdorster et al. 2005a). The 
second pathway involves a direct passage of the particle through the Blood Brain Barrier (BBB). This 
physiological barrier controls the passage of substances from the blood into the central nervous system. 
The permeability of this barrier is highly restricted to molecules which are either lipophillic, actively 
transported or are small soluble molecules (< 500 Da). This barrier may therefore represent a strict 
defense mechanism from blood borne particle exposure that limits the distribution of NPs to the brain. 
However, evidence exists that distribution to the brain might occur for some NPs, since low 
concentrations of gold were found in the brain after oral administration of gold (4-58 nm) NPs (Hillyer 
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and Albrecht 2001). It is suggested that the surface area of NPs is important in blood-brain integrity and 
need consideration as to their role in brain toxicity and brain distribution (Borm et al. 2006). Moreover, 
specific coating of NPs and nanoencapsulates are intended to create the possibility for the development 
of nanosized drug delivery systems to enable specific blood brain barrier crossing and distribution to the 
brain (Silva 2007). 
4.2.3 Metabolism 
Once NPs are absorbed by the gastrointestinal tract, these particles will be transported directly to the 
liver via the portal vein. The liver is able to actively remove compounds from blood. At this moment 
there is no evidence that this “first pass effect” also plays a role for any type of NPs. In general, this first 
pass effect can be considered as an elimination mechanism of the parent compound. For that reason oral 
bioavailability (fraction of the dose administered which reaches the systemic circulation) often is lower 
than the fraction absorbed from the intestinal lumen.  A study in rats showed a rapid elimination of 
polystyrene NP (50 nm) following single intravenous administration. These particles distributed 
predominantly in the hepatocytes and Kupffer cells in the liver. Twenty four hours after intravenous 
administration. 4% of the dose was excreted via the biliary route (Ogawara et al. 1999; Ogawara K. 
1999). 
Studies on metabolism of NPs have not been reported thus far. It is unlikely that inert NPs such as gold 
and silver particles, fullerenes and carbon nanotubes, can be metabolized effectively by enzymes in the 
body. However, it could be hypothesized that specific NPs with functionalized groups can be 
metabolized. For instance, the protein cap of a functionalized quantum dot could be cleaved by 
proteases ((Hardman 2006). Then the metallic core of quantum dots (and other metal oxides) could be 
bound by metallothionein and excreted. These enzymes, present in liver and kidney, can bind metal and 
restore the cellular metal homeostasis (Coyle et al. 2002). In addition, NP drug delivery systems 
consisting of liposomes are able to fuse with cell membranes. The intracellularly released drug could be 
metabolised according to the normal metabolism pathway described for the conventionally formulated 
drugs. 
Borm (Borm et al. 2006) posed several mechanisms for elimination of NPs. Free particles are likely to 
be removed from the circulation via phagocytic cells in the reticulendothelial system and hence will 
accumulate in organs such as liver and spleen. The consequence of nanoparticle uptake by macrophages 
is not yet known, there is evidence that it may stimulate the production of proinflammatory cytokines as 
was shown in alveolar macrophages (Brown et al. 2002) and then affect the functioning of e.g. the liver.  
4.2.4 Excretion 
An absorbed NP in the systemic circulation can be excreted by various routes. They can be distributed 
to the liver, taken up by hepatocytes and excreted in the bile to the gastrointestinal tract. Another 
possible elimination route for NPs could be renal clearance. Indeed, this latter route has been found to 
clear fullerenes and single walled carbon nanotubes (SWCNT) from the body (Rajagopalan et al. 1996; 
Singh et al. 2006). The plasma half-lives following intravenous injection in rats have been determined 
for several NPs (C60; C82; SWCNT) (Cagle et al. 1999; Rajagopalan et al. 1996; Singh et al. 2006). 
Interestingly, the study with C82 fullerenes suggested a prolonged circulation time compared to the C60 
Since, the fullerenes used in these studies have different functionalized groups it was suggested that not 
only size but also the chemical properties of NPs influence its excretion (Sayes et al. 2004) 
A size dependent excretion has also been suggested via bile. After intravenous administration in rats, 
polystyrene NPs were taken up by the liver and subsequently excreted in the bile. These particles larger 
(50 nm) were phagocytosed by Kupffercells partly and partly taken up by the hepatocytes, whereas 
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polystyrene microparticles (500 nm) were taken up predominantly by the non-parenchymal cells 
(Kupffercells and endothelial cells) (Ogawara et al. 1999). 
4.2.5 Summary /interpretation of ADME 
Taken together, the toxicokinetic properties of NPs for the Absorption, Distribution, Metabolism and 
Excretion (ADME) processes seem to depend strongly on the size of the particles as well as on the 
charge, additional functionalized groups and other novel physico-chemical properties. Thus no general 
conclusions on ADME processes for NPs can be drawn. This was to be expected because NPs cannot be 
considered as one sort of compound. Exposure within tissues and organs might for that reason become 
higher than following an equivalent dose of the conventional chemicals form (Preining 1998). As stated 
before, study results from various studies can hardly be compared due to a lack of proper dose metrics 
and characterization of the NPs applied in the studies, which hampers to establish a relationship 
between physicochemical properties and kinetic behavior (as is more or less the case for conventional 
chemicals). No coherent set of studies regarding certain types of NPs appeared even to be available. 
Animal studies have indicated nanoparticle absorption through the intestine and subsequent distribution 
to several target organs (including the liver, spleen, kidneys, bone marrow, lungs and brain). Due to the 
potential impact on toxicological effects, special attention needs to be paid to observations that some 
NPs are capable of crossing biological barriers such as the blood-brain barrier and the placenta. Also on 
cellular level, barriers such as cell membranes do not constitute obstacles for some tested NPs. The 
excretion of NPs (metabolic and elimination processes) remain poorly understood.  
For nanoencapsulates (including its contents) the distribution and elimination is thought to be influenced 
by the interaction with the reticuloendothelial system, which is composed of phagocytic cells in the 
liver, spleen and lymph nodes. These nanoencapsulates may end up in liver and/or spleen, which may be 
different from the target organ for the conventional form of the (non encapsulated) compound. 
Moreover, they may end up in different cell organelles and/or persist there for a longer period. Also, 
compounds that are normally prevented from entering an organ by a specific barrier may now enter this 
organ when presented as a nanoencapsulate. This opens up the possibility of specific drug targeting to 
organs and cells which would otherwise not be treated effectively. 
Since the effects of particle size, charge, coating and other phycisochemical properties on the kinetic 
behavior of NPs and nanoencapsulates are unknown in great detail, future research should focus on 
determination of the specific kinetic parameters and processes such as the half-live and elimination 
(metabolism and excretion) routes in several species. Also the distribution of the particles to target 
organs and the transplacental and blood-brain barrier passage should be studied in more detail to ensure 
safe application of nanoparticle containing consumer products. As validated toxicokinetic data of more 
NPs will become available, more reliable extrapolation to other exposure scenarios than applied in the 
study will become possible in the (near) future. 
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4.3 Toxicodynamics of nanoparticles 
Most information on the potential toxicity of NPs is available from inhalation toxicity studies in animals 
and humans. For the use of NPs in food, however, oral exposure is the most important route of 
exposure. The following paragraphs give an overview of the available information on the toxicity of 
NPs after oral exposure and if not available, also for other exposure routes. It should be kept in mind 
that results are often obtained for only one type and size of NPs. Extrapolation from one type of NPs to 
another, or from one size to another is on the basis of present knowledge still impossible.  At this 
moment there is too few data to draw conclusions for which type of effects are to be expected for which 
type of NPs..  
4.3.1 Acute and subchronic toxicity 
Acute, subacute and subchronic toxicity after oral exposure have been investigated in rodents for several 
different NPs (see Table 4.1 and Annex 2).  
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Table 4.1: Summary table of available oral toxicity studies of NPs 
Study Species Nanoparticle Results  Reference 
Acute and 
subacute 
toxicity 
Rats C60 polyalkyl-
sulfonate 
No mortality after doses up to 
2500 mg/kg 
(Chen et al. 
2006c) 
Acute toxicity Mice Zinc (58 + 16 NP) Increased mortality, renal 
damage and anemia after 5 
mg/kg compared to microscale 
zinc (1.08 + 0.25 µm) 
(Wang et al. 
2006) 
Acute toxicity Mice Copper (23.5 NP) Increased mortality, renal, liver 
and spleen damage compared to 
micro-particles  
(Chen et al. 
2006c) 
Acute toxicity Mice Titanium dioxide 
(25 and 80 NP) 
No increased mortality, but 
increased liver and kidney 
damage compared to fine 
particles (155 NP) 
(Wang et al. 
2007) 
Acute toxicity mice Selenium  Lower acute toxicity compared 
to selenite (LD50 113 compared 
to 15.7 mg/kg bw) 
(Zhang et al. 
2005) 
Short term 
toxicity 
Mice Selenium (20~60 
NP) 
Less oxidative stress, liver 
injury and growth retardation 
compared to selenite 
(Zhang et al. 
2005) 
Subchronic 
toxicity 
Rats Selenium (20~60 
NP)  
Less toxic than selenite and 
high-selenium protein 
(Jia et al. 2005) 
Acute and 
subchronic 
toxicity 
mice cationic PAMAM 
dendrimers 
Three animals died after single 
administration of 45 mg/kg and 
liver toxicity was observed after 
multiple dosing. 
(Duncan and 
Izzo 2005) 
Acute toxicity mice pure and N-doped 
carbon multi-walled 
nanotubes 
No signs of distress or tissue 
changes.  
(Carrero-
Sanchez et al. 
2006) 
Acute toxicity mice nano-magnetic 
ferrrofluid 
(magnetic particles 
about 19.9 NP) 
Low toxicity  
(LD50: >2104.8 mg/kg, 
maximum non-effect dose 
(ED0): 320 mg/mg) 
(Xia 2005) 
 
The results of the available oral toxicity studies indicate that, depending on the particle size, coating and 
chemical composition of the NPs, acute toxicity at high doses may occur. The main target organs appear 
to be the liver and kidney, but adverse effects in the blood, heart and spleen have also been observed. No 
information on the toxicity after chronic or acute low dose oral exposure is available.  
4.3.2 Toxicity of cardiovascular system 
Cardiovascular effects have been observed following inhalation exposure. These effects may be caused 
directly by NPs entering the blood or indirectly by inflammatory reactions in the lungs (Borm et al. 
2006; Tran et al. 2005). In case of a direct mechanism of action, particles absorbed by the lung 
 RIKILT /RIVM Report 2007.014 54 
endothelium and present in the central blood circulation might have direct effects on the endothelium, 
plaques and thrombogenic mechanisms (Tran et al. 2005). Although cardiovascular effects have not 
been described yet after oral exposure, it might be considered a plausible effect of systemically available 
particles.  
In addition to the described effects on lung, liver, brain and cardiovasculair system, NPs may reach the 
heart and the bone marrow where they may affect the cardiomyocytes and other cells of the heart 
directly (Tran et al. 2005) or cause a variety of effects on immunity and haemopoesis respectively 
(Oberdorster et al. 2005a; Tran et al. 2005). 
4.3.3 Toxicity of reticulo-endothelial system 
As stated before the liver is important to actively remove compounds from the blood of the portal vein: 
the “first pass effect”. In the gastrointestinal tract phagocytotic cells are in place to also actively remove 
particles. This reticulo-endothelial system consists of cells (macrophages, monocytes, and specialised 
endothelial cells) that have the ability to phagocytose cellular debris, aged cells, pathogens and foreign 
substances including NPs from the blood stream. In this way potential pathogens that enter the body 
from the gastrointestinal tract microflora are removed and neutralized. The consequences of 
nanoparticle uptake are unknown, however, in vitro studies demonstrated the generation of 
proinflammatory cytokines via reactive oxygen species and calcium signaling. Oxidative stress is 
known to inhibit hepatocyte function and bile formation, while pro-inflammatory cytokines are also 
associated with the pathology of liver disease. Hence, the impact of NPs on the liver and reticulo-
endothelial system needs to be investigated (Borm et al. 2006). 
4.3.4 Neurotoxicity 
The Blood Brain Barrier (BBB) forms a physiological barrier that limits the distribution of NPs from the 
blood to the brain. NPs can, however, to some extent enter the brain and a number of pathologies, 
including hypertension and allergic encephalomyelitis, however have been associated with increased 
permeability of the BBB to NPs in experimental setups. Conversely, the nanoparticle surface charge has 
been shown to alter blood-brain integrity (Borm et al. 2006) and needs consideration as to its role in 
brain toxicity and brain distribution (Borm et al. 2006). Moreover, specific coating of nanoencapsulates 
may also enable the encapsulates to cross the BBB and enter the brain (Silva 2007). In addition, a 
number of pathologies, including hypertension and allergic encephalomyelitis, have been associated 
with increased ability of NPs to penetrate the BBB in experimental setups. 
The potential impact of NPs on human neuronal tissue is as yet not investigated in detail. However, NPs 
have been shown to induce the production of reactive oxygen species and oxidative stress has been 
implicated in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's 
disease. It is conceivable that the long term effects might include a decrease in cognitive function. 
Increased markers of inflammation and AB42-accumulation in frontal cortex and hippocampus in 
association with the presence of NPs have been found. Additionally, inhalation exposure of BALB/c 
mice to particulate matter showed that activation of pro-inflammatory cytokines in the brain of exposed 
mice. Whether this is due to the fraction of combustion NPs remains to be investigated (Borm et al. 
2006). 
4.3.5 Reproduction toxicology 
The potential of NPs to enter the blood implies the possibility of transfer to reproductive organs and of 
transfer across the placenta leading to embryotoxicity (Fujimoto et al. 2005).Data addressing the 
distribution of NPs to the reproductive cells are, as yet, unavailable. In addition, no clear data are 
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available identifying the distribution of NPs in the fetus. There is a need to understand the toxicokinetics 
of NPs as it relates to placenta and foetus and teratogenicity of NPs in general (Tran et al. 2005) 
4.3.6 Mutagenicity 
It seems that on the cellular level, barriers such as cell membranes do not constitute obstacles for NPs. A 
great number of interactions with cell components are conceivable for particles penetrating into a cell. 
However, the health implications of such possible interactions are still unknown (UBA, 2006). During 
interaction with biological tissues, various factors are important such as material composition, electronic 
structure, bonded surface species (e.g., metal-containing), surface coatings (active or passive), and 
solubility, including the contribution of surface species and coatings and interactions of NP with other 
environmental factors (e.g., UV activation; (Nel et al. 2006). Recently, SCENIHR (SCENIHR 2006) 
concluded that there is a clear need for validated in vitro assays for nanoparticle evaluation, including 
assays with meaningful endpoints for genotoxicity. Also important to note is that carcinogenic effects 
for some particles are a consequence of inflammation which would not be detected by “classical” assays 
of genotoxicity (Donaldson et al. 2007). 
4.3.7 Allergenicity (sensitization) 
A further issue relevant for the exposure to NPs via food relates to the interactions of NPs with other 
food components. For example food containing NPs with actively charged surfaces can absorb 
biomolecules as they pass through the GI tract (Govers et al. 1994). These so called 'Trojan horses' 
(Lomer et al. 2002) may transport toxins into the intestinal mucosa, resulting in changed exposure of the 
cellular lining of the intestine (Borm and Kreyling 2004). It has been show that this altered presentation 
can affect the local immune response, a mechanism suggested to be related to Crohn's disease (Lomer et 
al. 2002). This latter mechanism might relate to possible (local) intolerance and/or allergenic responses 
of NPs. In addition the surface properties (e.g. coatings) are important determinants for the active 
uptake of encapsulates, but might also be a reason for concern. For example lectins used for coatings are 
highly immunogenic, can be cytotoxic or induce inflammatory responses and gastrointestinal irritation 
(des Rieux et al. 2006; Gabor et al. 2004). 
Even for normal chemicals, risk assessors are confronted with a lack of knowledge on the induction of 
food allergy and the type of exposure required to induce such responses. The possible adjuvant activity 
of NPs described above however introduces additional uncertainty. If a food allergy to a NP is 
established, labeling and traceability is considered to be critical to anticipate and exclude possible 
sources for such potential allergens (Kroes et al. 2002). 
4.3.8 Summary /interpretation of toxicology  
In short, the results of the available toxicity studies indicate that acute oral exposure to large amounts 
may induce toxic effects mainly in the liver and kidney, but also in the blood, heart and spleen. No 
information on the chronic toxicity after low dose oral exposure is available (SCENIHR 2006). 
Information from toxicity studies with other exposure routes indicate that several systemic effects on 
different organ systems may occur after exposure to NPs, including the immune, inflammatory and the 
cardiovascular systems. Effects on the immune and inflammatory systems may lead to oxidative stress 
and/or activation of pro-inflammatory cytokines in the lungs, liver, heart and brain. Effects on the 
cardiovascular system may include pro-thrombotic effects and adverse effects on the cardiac function 
(acute myocardial infarction and adverse effects on the heart rate). Furthermore, genotoxicity, and 
possible carcinogenesis and teratogenicity may occur, but no data on these latter endpoints are available 
yet. 
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Despite all previous research done on NP, scientific knowledge on the potential toxicology of NP is 
limited. NPs may have an increased toxicological profile when compared to their conventional 
counterparts. Furthermore, the question arises whether the standard battery of tests in protocol 
toxicology is useful for the detection of the different toxicological profile of NP as not all effects 
identified above are routinely studied in these tests. 
Future research should focus on validated in vitro assays for nanoparticle evaluation, including assays 
with meaningful endpoints for genotoxicity. 
4.4 Exposure assessment  of nanoparticles 
Human beings are continuously exposed to natural and unintentionally produced NPs (e.g. fine dust 
particles, sand dust). Exposure assessment includes the entire life cycle of nanomaterials from synthesis 
to disposal. Likely, inhalation is the most important route of exposure to these NPs. If expressed in 
number of particles, per breathe ca 4x106 particles are inhaled, of which more than half remains in the 
lungs (Engineering. 2004). Direct oral exposure via food to NPs is estimated to be 1012-1014 micro- and 
NPs per person per day (mainly silicates and titanium dioxide) (Lomer et al. 2004; Lomer et al. 2002). 
Indirect exposure of the gastrointestinal tract can also be expected due to clearance of in the lungs 
deposited NPs via the mucociliary escalator (coughing up and swallowing of inhaled NPs). The 
contribution of the latter exposure route to the total amount of NPs, however, has not been quantified. 
In the two sections below relevant food exposure sources will be explored followed by an analysis of 
special requirements that NPs pose on the exposure assessment as currently employed for normal 
chemicals. 
4.4.1 Data requirements and methodology 
Exposure assessment is defined as the qualitative and /or quantitative evaluation of the likely intake of 
biological, chemical or physical agents via food as well as exposure from other sources if relevant 
(WHO, 1997). To perform an exposure assessment the following type of information is needed (Kroes 
et al. 2002): 
• Which substances are present in which amounts in a given food and/or the diet in general and what 
affects their levels and characteristics, especially their biological activity? 
• How much of the foods containing these substances are consumed and what is the consumption of 
potentially relevant risk groups, including high and frequent users? 
• What are the conditions and the probabilities of consuming occasionally or regularly high amounts 
of such foods which at the same time contain high levels of the substance(s) in question? 
 
Basically, the principle of exposure assessment of NPs (via food) will be comparable to the exposure 
assessment of ‘normal’ chemicals. However some aspects do require specific attention, these will be 
highlighted below. 
 
Amount of NPs present in food commodities 
A central aspect of exposure assessment is the determination of the amount and characterization of the 
NPs (or normal chemicals) present in the food as consumed (see chapter 3). Issues like food sampling 
and variability within composite samples and variation in concentrations between samples are not 
different from the exposure assessment of normal chemicals.  
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For an exposure assessment of nanoscale delivery systems loaded with bioactive compounds or 
bioactive compounds themselves in nanoscale formulations, both the amount of bioactive compounds 
within the capsules as well as the free form in the food matrix has to be determined. For this, the 
analytical isolation, detection and characterization procedures need to be designed to meet these 
requirements. 
The presence of NP in the food matrix might result in increased bioavailability of substances (both 
nutrients and contaminants) normally present in the food. This needs to be considered when the 
presence of NPs in food is known.It will not always be feasible to measure chemicals and NPs in the 
food matrix in the consumable form. If chemicals are measured at an early stage of the food chain, 
effects of processing should be considered in exposure assessment (Kroes et al. 2002). The influence of 
processing at the stage of household preparation is, like in the exposure assessment of normal 
chemicals, also important (Kroes et al. 2002) for NPs. However, the default or database derived 
processing factors that are being used for determination of exposure assessment of normal chemicals 
when the exact effect of processing is unknown, (e.g. pesticides (JMPR)), are not (yet) available for 
NPs. 
 
Consumption 
Various sources of consumption data are currently utilized ranging from standardized food baskets used 
in pre-marketing authorizations to household or individual dietary surveys used in post-marketing 
studies (Kroes et al. 2002). There are no additional requirements for consumption data to be able to 
perform an exposure assessment for NPs that can be expected to be present in a variety of products (e.g 
residues of nanopesticides, processing aids or packaging materials). The use of NPs as additive or in 
special foods (novel foods or supplements) might require additional data on consumption of these 
special foods, because this information is generally lacking in the regular consumption databases. This 
is of course a general problem for exposure assessments, but more prominent in evaluating NPs because 
these particles are incorporated frequently in food supplements (see chapter3). 
 
Intake calculations 
The last step in performing the exposure assessment is the integration of food consumption and amount 
of chemicals or NPs present in food. Usually one of the following three approaches is applied for this 
integration of data: 1) point estimated; 2) simple distributions; 3) probabilistic analyses (Kroes et al. 
2002). In the end the consumer exposure will be compared to a to a toxicological reference value e.g. 
tolerable daily intake, acceptable daily intake or acute reference dose or nutritional reference values like 
recommended daily intake or upper safe intake levels. These reference values are lacking for NPs and 
need to be established. 
4.5 Risk Assessment of nanoparticles 
As with conventional chemicals, risk assessment will be the basis of assessing and regulating 
nanomaterials (in food) to protect human health and the environment.  
4.5.1 Establishing health-based guidance values 
The last step in the hazard characterization is the setting of health-based guidance values such as 
acceptable daily intakes (ADIs) for food additives and pesticide residues, and tolerable daily intakes 
(TDIs). These values are based on the data from (animal) studies as indicated above. Reference points 
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(e.g. the no-observed-adverse-effect-level or benchmark-dose-level) for the most critical effect of a 
substance forms the reference point for the risk assessment. This is a general approach for all substances 
either being in a conventional form or at a nano-sized scale. In the case of health-based guidance values 
some issues require special attention. 
For NPs, dose-response relationships will have to be analyzed case by case using different dose-
describing parameters. As already mentioned before, the size of NP is not the only critical factor to 
explain the novel properties of NP but also the overall number (e.g. total surface area) may be relevant. 
So simply using mass in dose metrics will not be sufficient. However, up till now it has not been 
possible to establish a single alternative dose-describing parameter that best describes the dose and the 
observed dose response relations in toxicological tests.  
A second issue is the biological activity of NPs present in food. The health-based guidance values are 
based on toxicological studies performed with NPs with a given bioavailability. NPs are often 
introduced to enhance the bioavailability of either themselves, or of the bioactive compounds loaded 
into them (nanoencapsulates) of to affect the uptake of other nutrients (or contaminants) present in the 
food. If by some means the bioavailability is changed (increased), this may affect the outcome of the 
toxicity studies and thus the calculated guidance values. Extrapolation of an health-based guidance 
value between formulations with different bioavailability might not be possible. Ultimately, this might 
require setting of separate values depending on the formulation. 
4.5.2 Combining hazard and exposure 
For risk assessment both information on exposure as well as on the (intrinsic) toxicity (hazard) of a 
compound is required. Determining potential consumer exposure is first of all important to assess the 
potential risk for consumers. Keeping in mind Paracelcus quote “Alle Ding sind Gift und nichts ohn 
Gift; allein die Dosis macht, das ein Ding kein Gift ist”(All things are poison and nothing (is) without 
poison; only the dose makes that a thing is no poison). Thus the dose of NPs present in food needs to be 
determined. As stated earlier, engineered NPs can have novel toxicological properties, that are attributed 
to their small size, chemical composition and surface structure (Nel et al. 2006). Since it has not been 
possible to establish a single dose-describing parameter that best describes the toxic effect , NPs should 
be characterized as completely as possible (Oberdorster et al. 2005a; Powers et al. 2006; Thomas and 
Sayre 2005). A further complicating factor is that the physico-chemical characteristics of NPs are highly 
depending on the matrix in which they are present (Oberdorster et al. 2005a; Powers et al. 2006). Thus 
NPs needs to be characterised in the food matrix (e.g. in situ). 
Because of these uncertainties both in hazard assessment of NPs and in the exposure assessment, it is 
very important for risk assessors to have access to a clear description of the analytical methods that were 
used to determine the physicochemical properties of the respective NP, to have access to the (raw) 
experimental data and a sound description of the statistical procedure used to analyze the data. Only 
then a reliable assessment of the NPs can be performed and only then the results of the safety 
assessment can be used to model NP properties in silico (Powers et al. 2007), or compare results with 
those of non-nano counterparts. Another problem may be the comparison of different particle sizes and 
forms of the same compound. This problem is given in by the fact that proper dose metrics are still 
lacking. 
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5 Review of food related legislation and guidance documents related to 
nanotechnology in food 
Different engineered nano-scaled materials are or will be used in food products, will end up in food as 
residues or contaminants and, are or will be used in products in contact with food, this is indicated in 
detail in chapter 3. Examples are nanoscaled food additives, micronutrients or essential elements, 
residues of nanoscaled pesticides or veterinary drugs, or 'intelligent' nano-contituents of food packaging 
material. Also nanoscaled encapsulates to deliver micronutrients or other food components at the 'right' 
sites in the body are being developed. 
For most of these substances legislation already exists for the same materials of conventional chemicals. 
For 'regulated' substances, substances that are not allowed on the market unless they have been 
authorized, in general a safety assessment will have been made before market entry. In order to conduct 
a safety assessment sufficient toxicological hazard information should be made available by the 
producers of the substances. This will also be the case for nanosubstances subject to authorization. 
Another aspect is the monitoring of nanoparticles (NPs) in the food chain. Also for the official 
monitoring legislation is already existent.  
In the existing legislation however, no reference is made to nanotechnology. In the next paragraphs the 
legislation concerning the use of NPs in relation to food, and the legislation concerning the official 
monitoring will be discussed. Potential gaps in the regulation are presented. Furthermore possible 
necessary modifications in legislation with respect to nanotechnology products are given. 
5.1 Methodology 
In this project only overarching reviews were used to present an outline of regulations that are 
applicable in the case of use of engineered NPs in or in contact with food, and residues of or 
contamination with nanomaterials of food. Especially the review presented by Frater (Frater et al.  2006) 
and the regulatory review of the Food Standards Agency of the UK (FSA March 2006) were used 
intensively. The original legislative texts were examined only occasionally due to time and money 
constraints. If European legislative texts were consulted, the consolidated versions as presented on the 
Eur-lex website were used. 
5.2 Discussion of food related legislation and guidance documents  
Most of the legislation on food in the Netherlands is based on European Directives and Regulations. The 
following sections will describe briefly the regulations and the potential gaps in the legislation on food 
when NPs are considered. 
5.2.1 The General Food Law. 
For the purpose of the European General Food Regulation ((GFL) (EC/178/2002.)) food or foodstuff 
means (article 2) 'any substance or product, whether processed, partially processed or unprocessed, 
intended to be, or reasonably expected to be ingested by humans'. The GFL therefore also applies to 
food substances/products of nano-size expected to be ingested by humans. 
According to the GFL all foods placed on the Community market must be safe, or as stated in article 14 
sub 1: 'Food shall not be placed on the market if it is unsafe'. Unsafe is defined as' injurious to health' 
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or 'unfit for human consumption'. In making an assessment of food safety article 14 requires to take into 
account among others probable immediate, short term and/or long term effects on the consumer and 
subsequent generations. The GFL stipulates that it is the responsibility of 'food business operators' to 
ensure that their foods satisfy the requirements of food law. Furthermore the food business operator 
should be able to trace one step up and one step down 'any substance intended to be, or expected to be, 
incorporated into a food (article 18). To facilitate traceability food should be adequately labeled or 
identified (article 18 sub 4). 
In paragraph 18 and article 6 of the regulation it is emphasized that in decision making, scientific risk 
assessment should be central. The precautionary principle is laid down in this regulation in article 7. 
This article stipulates that if after assessing the available information a possibility of harmful effects on 
health is identified but scientific uncertainty persist, risk management measures to ensure a high level of 
health protection may be adopted, pending gathering and developing further scientific information for a 
more comprehensive risk assessment. 
 
Items to be considered: General Food Law 
 The assessment of safety for some of the NPs that are to be used in food products will not be 
possible due to a lack of knowledge on likely effects of these NPs. A lack of data on safety of 
NPs may provoke the precautionary principle. The management measures adopted in this case 
should however be among others 'proportionate', and should be reviewed within a reasonable 
period of time (article 7 sub2).  
 A requirement in the GFL is that member states should monitor to verify if the requirements of 
food law are fulfilled by food business operators (article 17). Also the European Food Safety 
Authority should, according to article 34, establish monitoring procedures to identify emerging 
risks. The monitoring of NPs will require the development of new analytical detection and 
confirmation techniques. 
5.2.2 Novel food and novel food ingredients 
The Novel Food Regulation (EC/258/97) concerns the placing on the European market of novel food 
and novel food ingredients. Novel is defined in this Regulation as 'not hitherto been used for human 
consumption to a significant degree within the Community'. With 'not hitherto' May 15, 1997 is meant, 
the date the regulation came into force. Only 'novel' foods are regulated, furthermore the food and food 
ingredients must fall in one or more of the following categories (article 1): 
- food and food ingredients with a new or intentionally modified primary molecular structure; 
- food or food ingredients consisting of or isolated from micro-organisms, fungi or algea; 
- food and food ingredients consisting of or isolated from plants, or isolated from animals, except for 
foods and food ingredients obtained by traditional propagating or breeding practices and having a 
history of safe use; 
- foods and food ingredients to which has been applied a production process not currently used, where 
that process gives rise to significant changes in the composition or structure of the foods or food 
ingredients which affect nutritional value, metabolism or level of undesirable substances. 
The Regulation does not apply to food additives and flavorings, and extraction solvents used in the 
production of foodstuffs, as for these substances, in most cases, other legislation applies. 
Novel foods and novel food ingredients must not present a danger for the consumer, mislead the 
consumer or differ from foods or food ingredients which they are intended to replace to such an extent 
that their normal consumption would be nutritionally disadvantageous for the consumer (article 3). 
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Before a novel food or novel food ingredient is authorized a safety and nutritional assessment is made 
by the member state where the novel product will placed on the market for the first time. The quite 
extensive data requirements for this assessment are laid down in Commission Recommendation 
97/618/EC. 
 
Items to be considered: Novel Foods 
 The Novel Food regulation does not address the size or shape of novel food ingredients. It does 
however address 'production processes not currently used' so nanotechnology as such is likely 
to fall under the regulation because of its novelty. It is not clear if the use of NPs in foods that 
are already on the market makes these foods 'novel' and thus requiring authorization. If 'old' 
ingredients are marketed in future in nano-sized forms, it is not certain that this regulation will 
apply. 
 Article 3(4) of the regulation says that when certain food components are 'substantial equivalent' 
to their conventional counterparts they can be treated in the same manner as their counterparts. 
Only the 'equivalency' has to be proven. It is likely that some engineered NPs will be 
'equivalent'. However article 3(4) only applies to certain categories of food and food 
ingredients, engineered NPs do not fall into the categories mentioned thus far in this regulation 
(the Regulation is under revision at this moment however). 
5.2.3 Food additives, enzymes, flavorings and processing aids 
In the European Union food additives are not allowed to be present in food unless they are authorized 
for use. According to European legislation on food additives, consisting of a framework Directive 
(89/107/EEC) and three specific Directives (94/36/EC (colors), 94/35/EC (sweeteners) and 95/2/EC 
(food additives other than colors and sweeteners)) and their amendments, food additives may only be 
authorized if there is a technological need for their use, if they do not mislead the consumer and if they 
do not present a health hazard to the consumer. Lists of permitted additives, the foods in which they can 
be used and, if necessary, maximum levels of use are present in the annexes of the additive directives. If 
no quantitative limits are set the maximum use of additives should still be limited by the necessity to 
achieve the desired technological effect (quantum satis). Furthermore additives must comply with 
specific purity criteria laid down in other directives.  
So, before authorization ample information concerning the physico-chemical properties and toxicity of 
the additive have to be provided by the producer. Or as is stated in Annex II of 89/107/EC: 'to assess the 
possible harmful effects of a food additive or derivatives thereof, it must be subjected to appropriate 
toxicological testing'. The safety assessment for food additives is nowadays performed by EFSA (panel 
on dietetic products, nutrition and allergies), previously by the Scientific Committee on Foods (SCF). 
The scope of the food additive framework Directive 89/107/EC only covers enzymes used as food 
additives and not the use of enzymes as processing aids. Under 95/2/EC the use of two enzymes as food 
additives are allowed: an invertase and a lysozyme. 
A size restriction ('not less than 5 µm') is, up till now, laid down for only two authorized food additives: 
microcrystalline cellulose and powdered cellulose, for safety reasons (96/77/EC). Form of the additive 
played a role in the authorization of titaniumdioxide. Originally only the anatase form was authorized. 
The rutile (platelet) and anatases forms of titanium dioxide are similar chemically but differ in their 
crystalline structure and light reflectance. The SCF concluded in her safety assessment on the rutile 
form that on the basis of a new bioavailability study in which different rutile and the anatase form were 
given orally to rats, that the bioavailability of the different form was essentially the same, and that the 
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toxicological database for the anatase form would be applicable to either form (EFSA 2004). 
Subsequently also the rutile form was named in a Directive, member states should include the rutile 
form in their legislation on food additives before April 10 2007 ((2006/33/EC.)). 
Flavoring substances are up till now regulated by a separate Directive, Council Directive 88/388/EEC.  
In Directive 88/388/EEC a definition of 'flavoring' is given. Flavorings can be derived from plant and 
animal species or by chemical synthesis. The flavorings made by chemical synthesis are subdivided in 
this Directive in 'nature identical' and 'not chemically identical to a substance naturally present'. For 
certain undesirable substances (like safrole, coumarin, thuyone) present in foodstuffs due to flavoring or 
food ingredients maximum levels are set for some specified foods (Annex II). These substances may 
however not be added as such to foodstuffs or flavorings, so the mass limits set here are not a problem. 
The food additives Directives do not cover processing aids like most of the enzymes used and extraction 
solvents. 
In the near future the European legislation on food additives, enzymes and flavorings will change. Use 
of enzymes will be covered by the future legislation. Proposals for Regulations on these issues (COM 
(2006) 425 final, COM (2006) 428 final, COM (2006) 427 final) were published July 2006, as was a 
proposal for a Regulation establishing a common authorization procedure (COM (2006) 423 final). 
Once accepted by the European Parliament and Council these Regulations will replace the current 
Directives. 
No European proposal for a Regulation or a Directive on processing aids (other than enzymes) is 
formulated yet. 
 
Items to be considered: Food additives 
 On new ‘nano-additives’ existing food additives legislation will apply as it is likely that the 
nano-additives that are being developed will fall within the definition of a food additive (article 
1 of 89/107/EEC) and will be used for the same reasons e.g. needs as the food additives 
authorized today. As for the toxicity tests to be performed, as stated previously under 'hazard 
characterization' (chapter 4.2 and 4.3), dose metrics should include information on the nano-
properties of the substance.  
 It is not clear if when an already authorized food additive is reformulated in nano-size this 
means that it is a new additive. However all authorized food additives must according to point 4 
in Annex II be kept under continuous observation and must be re-evaluated whenever necessary 
in the light of changing conditions of use and new scientific information.  
 In the Directives on purity criteria for food additives properties related to particle size should be 
included. 
 A nano-flavor can be 'chemically identical' to a natural flavor but have a different toxicity 
profile due to properties related to its-nano-size. 
 It is likely that NPs for use in food processing are being developed that fall outside the scope of 
the Directives and the future Regulations 
 Although particle size was evaluated when authorizing two additives, in the 'purity criteria' 
Directives for food additives, size (with all its dimensions) is not mentioned (nor size 
distribution). 
5.2.4 Food enrichment 
A new European Regulation on the addition of vitamins and minerals and certain other substances to 
food has recently been published (EC/1925/2006.). It shall apply from 1 July 2007. In Annex I and 
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Annex II of this regulation vitamins and minerals (and the forms of the vitamins and minerals) are listed 
which may be added to food. The regulation requires that the nutrient added is in a bio-available form. 
Purity criteria for the vitamin formulations and mineral substances in the annexes shall be adopted in the 
near future. Addition to non-processed food and alcoholic beverages is prohibited. If a vitamin or 
mineral is added it is obligatory to provide for nutrition labeling. The regulation aims to harmonize the 
market of supplemented foods in the EU and to protect consumers from ingesting quantities of vitamins, 
minerals and other substances that could harm the health of the consumer. Most remarks in the next 
paragraph on food supplements (that are not copied here) are also applicable here. A difference however 
is that in EC/1925/2006 monitoring is mentioned, for monitoring nano-sized nutrients added to food 
analytical methods need to be developed that can provide information on the size of nutrients present.  
5.2.5 Food supplements 
Directive 2002/46/EC aims to harmonize the rules for marketing food supplements in the EU. A food 
supplement is defined as (article 2): 'Food supplements' means foodstuffs the purpose of which is to 
supplement the normal diet and which are concentrated sources of nutrients and other substances with 
nutritional or physiological effect, alone or in combination, marketed in dose forms, namely forms such 
as capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquid, drop 
suspensing bottles and other similar forms of liquids and powders designed to be taken in measured 
small unit quantities'.  
With nutrients vitamins and minerals are meant. In Annex I of the directive vitamins and mineral 
substances are listed which may be used in the manufacture of food supplements, Annex II contains the 
forms such as thiamin hydrochloride and thiamin moninitrate (vitamin B1), cyanocobalamin and 
hydroxycobalamin (vitamin B12), potassium fluoride and sodium fluoride (fluoride), and cupric 
carbonate, cupric gluconate, cupric citrate, cupric sulphate and copper lysine complex (copper). Purity 
criteria for the substances in Annex II will be adopted, unless purity criteria are already set in other 
Community legislation when the same substance is used for other purposes than covered by this 
directive. Member states may ban supplements from their markets that contain vitamins and minerals 
not included in Annex I or in forms not included in Annex II (article 4sub7). They may however also 
allow supplements containing vitamins and minerals and forms not listed in the annexes that were used 
in one or more food supplements marketed in the Community before 12 July 2002 and for which the 
EFSA has not given an unfavorable opinion. July 2007 the Commission will have prepared a report 
concerning the use of substances other than vitamins and minerals in food supplements. 
Producers of food supplements should take into account when choosing the amounts of vitamins and 
minerals present in food supplements per daily portion, the upper safe limits of vitamins and minerals as 
established by scientific risk assessment (taking into account the varying degrees of sensitivity of 
different consumers groups) and the intake of vitamins and minerals from other dietary sources. The 
manufacturer should declare on the label of a food supplement the amount (in mg, µg) of nutrients or 
other substances present, the amount per portion and expressed as a percentage of the reference value 
(e.g. the recommended daily intake). 
For minerals or trace elements particle size may be a determinant of oral absorption. Rohner and 
colleagues ((Rohner et al. 2007)) showed that lowering the size FePO4 (a poorly soluble iron 
compound) to nano size (10.7 NP) with a spherical structure increased its bioavailability in rats. These 
authors also mentioned studies in which it was established that the acute toxicity of nanoscaled copper 
and zinc were higher than those of equivalent amounts of micro-copper and micro-zinc.  
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For some essential nutrients such as vitamins and minerals the gap between the recommended dose and 
the toxic dose is narrow. Overdosing of minerals and (fat-soluble) vitamins can lead to adverse health 
effects. 
 
Items to be considered: Food supplements 
 Nanosizing of especially minerals may improve their bioavailability. Adjustment of amounts in 
supplements should take into account the improved bioavailability to prevent overdosing. 
 Purity criteria should include information on the size and form of the substance 
 Established maximum intakes may have to be revisited if nano-sized nutrients with improved 
absorption characteristics are added to food or present in food supplements. 
5.2.6 Materials coming into contact with food 
Engineered NPs to improve food packaging materials are being developed. These will improve for 
instance the strength or the barrier properties of the materials. Also antimicrobial engineered NPs will 
be used in packaging to extend shelf life and improve food safety characteristics and many other 'active' 
and ‘intelligent NPs', intended to come into contact with food are in the pipeline.  
All materials that come into contact directly or indirectly with food, including active and intelligent 
NPs, are subject to EC regulation (EC/1935/2004.). Active food contact materials and articles are 
defined as (article 2 sub 2a) 'materials and articles that are intended to extend the shelf-life or to 
maintain or improve the condition of packaged food. They are designed to deliberately incorporate 
components that would release or absorb substances into or from the packaged food or the environment 
surrounding the food'. 'Intelligent' means materials and articles which monitor the condition of packaged 
food or the environment surrounding the food (article 2 sub2b). Active and intelligent materials and 
articles need to be authorized (article 4 sub2) and should be adequately labeled (article 4 sub5-6). As 
according to the Regulation the active and intelligent materials shall be considered as ingredients 
(article 4 sub2), also the Directive on labeling of foodstuffs (2000/13/EC) applies. 
EC/1935/2004 requires among others that packaging materials and other articles coming into contact 
with food under normal or foreseeable conditions of use do not transfer their constituents in quantities 
that could endanger the consumer's health. Moreover the materials and articles should not bring about 
an unacceptable change in the composition of the food or deterioration in its organoleptic properties 
(article 3 sub-abc). As of 27 October 2006 business operators should be able to trace their packaging 
materials and articles one step up and one step down (article 17). Here again, traceability requires 
labeling or other measures to assure tracing. 
The EU has adopted more specific measures for plastic materials (2002/72/EC), regenerated cellulose 
(93/10/EC) and ceramics (84/500/EC). These specific directives contain positive lists of substances that 
may be used in food contact materials. For each category of substances restrictions on the migration are 
mentioned. Maximum migration levels are expressed in mass of substance per mass or volume of 
packaged food (.e.g. high = 5-60 mg/kg/food, low = <0,05 mg/kg/food).  
Migration of active and intelligent NPs into foodstuffs is a likely occurrence. Depending on the 
migration level of the NPs more or less safety data should be supplied to EFSA. The safety assessment 
is made by EFSA. 
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Items to be considered: Food contact materials 
 Expressing the migration levels in mass per mass or volumes does not take into account the 
possibility of changing toxicity profiles with the lowering in size of a substance. Migration level 
cuts offs in the legislation may therefore not be adequate for NPs.  
 Food contact materials with NPs falling in the low migration category for which a limited 
dataset is required may be authorized without a sufficient assessment of safety for man and the 
environment. 
 Because of the present lack of safety data also here the precautionary principle may be used to 
prevent NPs from being used in food contact materials. If member states suspect that a contact 
material endangers human health they may suspend the application within its territory (article 
18). 
5.2.7 Other (contaminants, pesticides, veterinary drugs) 
Due to the use of NPs in products like quantum dots or pesticide formulations foods may become 
contaminated with residues of the NPs. In de next sections attention will be paid to the legislation in the 
European Union concerning contaminants and residues. This because legislation in member states 
concerning contaminants and residues in food is to a large extent based on EU directives and 
regulations. The difference between 'residues' and 'contaminants' in EU law is that residues are the result 
of legal use of substances during food production whereas contaminants may be present in food as the 
result of their presence in the environment. The difference however is somewhat arbitrary, like for some 
older forbidden pesticides that are not used anymore but still contaminate food due to former usage. 
5.2.7.1 Contaminants 
EU regulation EC/1881/2006 sets maximum levels for certain contaminants in foodstuffs. Maximum 
levels for contaminants are set at levels that are reasonably achievable by following good agricultural, 
fishery and manufacturing practices. Also the risk related to the consumption of contaminated food is 
taken into account. Before maximum levels are set a risk assessment is made, nowadays in Europe by 
the EFSA scientific panel on contaminants. The result of a risk assessment is that maximum intake 
levels by humans are established, like Tolerable Daily Intakes (TDI) or (provisional) Tolerable Weekly 
Intakes (pTWI). The in vitro and in vivo studies used to evaluate the risk of contaminants are to a large 
extent published in scientific literature or performed by laboratories related to governments. From the 
description of these studies it is sometimes hard to derive the precise substance tested (sometimes no 
specification of the materials tested is given), information concerning size, three-dimensional structure 
or volume of the tested substance are always lacking.  
Taking into account consumption figures and background levels in food, maximum levels are proposed. 
The maximum levels of contaminants in food are expressed as concentrations, e.g. mg substance per kg 
food. The size of a substance is not included in the threshold value. NPs however may or will have 
different toxic properties than their non-nanoparticle counterparts. However also for 'normally' sized 
substances thresholds can be just an estimation of 'safe' limits. For example: cadmium (Cd) can be 
present in different forms like metallic Cd (not soluble), Cd-sulfide (low solubility) and Cd-chloride 
(very soluble). The oral LD50s in mice for Cd-sulfide and Cd-chloride are 1200 mg/kg bw and 94 
mg/kg bw respectively (Bellinger et al. 2004). It is not easy to take into account the different properties 
of all the different Cd forms in the establishment of pTWI and limits in food. The maximum limits 
established in Europe only mention 'cadmium' meaning 'total cadmium' irrespective of the Cd-
containing compound present. Also for mercury (Hg) and arsenic (As) for example the limits set for 
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total Hg and total As, and are not specified although it is known that the inorganic compounds of these 
heavy metals have a vastly different toxicity profile than the organic compounds. 
 
Items to be considered: Contaminants 
  Additional safety tests may be necessary to investigate if human health limits set (like TDIs, 
pTWIs etc) are still valid for nano-sized particle contaminants 
 Maximum levels set today for certain contaminants in food may be inadequate to protect the 
consumer health due to increased toxicity of the nano-size version of the contaminants. 
5.2.7.2 Pesticides used in crops 
The placing on the market of pesticides used to protect plant or products of plants is regulated by 
Directive 91/414/EC. Before a substance is allowed on the market to be used as a pesticide a safety 
assessment is made. Once a substance is approved member states may authorize the use of the substance 
in plant protection products. The safety assessment is meant to assure that when plant pesticide products 
are used correctly, no harmful effects will occur in persons applying the pesticide, consumers or 
domestic animals. Furthermore an assessment is made of the impact on the environment. EFSA peer 
reviews the assessments made. The use of pesticides may result in residues in plant products. Maximum 
Residue Levels (MRLs) are therefore set at a level in agreement with good agricultural practice (GAP) 
and taking into account human health based safety limits (ADIs). To set MRLs data from residue trials 
are evaluated. At this moment 4 EU directives contain the harmonized EU MRLs. Besides EU MRLs 
member states have national MRLs for substances not harmonized yet. In the near future there only will 
be EU MRLs in one Regulation (EC/396/2005). 
 
Items to be considered: Pesticides 
 Inclusion of nano-particles in pesticides where the non-nano form has already been authorized 
may require additional safety testing and a new approval 
 In the assessment of the residue data provided by the producer, ample consideration should be 
given to the (range of ) formulations as residue formation may be different due to the use of 
nanotechnology. 
 Nano-sized active constituents may have different toxicity and residue profiles than the same 
normal sized constituents, re-assessment of ADIs and MRLs may be necessary.  
5.2.7.3 Veterinary drugs 
Veterinary drugs are not allowed to be used unless they are registered. The registration for the use of a 
veterinary medicinal product is granted at the national level. However procedures, data requirements etc 
for registration are harmonized to a very large extent within the EU by Directive 2001/82/EC 
(2001/82/EC). Furthermore before any pharmacologically active substance is allowed on the EU market 
for use in food producing animals, maximum residue limits (MRLs) should be established on EU level 
(EEC/2377/90.). In human medicine developments on nanosubstances to enhance efficacy of drugs or 
improve diagnosis are well underway. In medicines used for treatment of animals NPs may also be used 
in future. The use of NPs as excipients or as active constituents to enhance efficacy may also result in 
alterations in the absorption, metabolism, distribution or excretion (ADME) of the active constituent(s) 
of the drug. Plus the toxicity, pharmacological and if applicable, antimicrobial profile of a nano-sized 
active constituent may be different from the evaluated normal size variant. So, established ADIs and 
MRLs may have to be revisited, or set for the nano-sized variants of active constituents. To this end data  
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concerning the characteristics of the nano-contituents in addition to those of the non-nano variant are a 
necessity. This is especially the case for nano-encapsulation of active constituents to improve drug 
delivery at target sites. In this case also the toxicity profile of the capsule could be of interest. 
 
Items to be considered: Veterinary drugs 
 If a nanomaterial is incorporated in an already registered veterinary medicinal product it is not 
sure if the product should be re-registered. Alterations in the composition of a product should be 
brought to attention of the registration authorities. An alteration in size in any of the substances 
used as constituents of a veterinary drug does not result in a change in chemical composition. 
However due to altered characteristics of nano-constituents compared to their non-nano 
equivalents, products should not be considered to 'essentally similar' without any confirming 
data. 
 Nano-sized active constituents may have different ADME and toxicity profiles than the same 
normal sized constituents, re-assessment of ADIs and MRLs may be necessary.  
 
5.2.8 Not food related legislation - REACH 
Present legislation on existing and new chemical substances and the new Regulation on chemicals 
(REACH, EC) do aim to obtain information on dangers of substances. Information should be supplied 
by the producer and the review of the data included in a notification ensures that the substance is labeled 
for supply, and that there is information to take the appropriate measures to reduce risk during use and 
disposal. Present Directives differentiate between existing (this is defined as: placed on the market 
before September 1981, and listed in EINECS (European Inventory of Existing Commercial Chemical 
Substances)) substances and new substances. Data requirements for new substances are more stringent. 
The new regulation REACH introduces testing requirements not only for the new substances but also 
for the ones previously called 'existing'. It is up to the producer to determine whether or not the nano-
substance he produced and which is on the EINICS list should be considered as existing (no new data) 
or new. In the old Directives as well as in REACH also the quantity of a substance produced determines 
the set of data on safety that has to be provided by the producer. These mass triggers may not be 
appropriate for nanochemicals.  
Additional safety testing and evaluation of nano-versions of chemicals for which safety evaluations 
were already made, is not required in the legislation on chemical substances, since the nanoscale form 
does not constitute a change in the chemical structure. In describing the chemical identity (CAS nr, 
EINECS nr) of substances no size-properties and size distributions of the chemical are demanded in the 
legislation. If no information on the presence of NPs in products is passed through the chain of 
production, transport, use and disposal, NPs will end up in the environment without anyone knowing it. 
If the nanomaterial turns out to be a hazardous substance to hold the producer responsible and trace any 
other introductions into the environment will be very difficult. Nano-substances may eventually end up 
in the food chain, and be regulated as contaminants. Adequate safety testing, including investigations on 
the fate in the environment, before use of the nanomaterial, may prevent the entrance of harmful nano-
substances as contaminants in food (and feed). 
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Items to consider: REACH 
 The adequacy of the quantity mass limits set in REACH in relation to nanochemicals 
 The addition of an indication of particle size characteristics to the chemical name or number, to 
differentiate the nano from the normal sized substances, and to make an additional safety 
assessment for nano-varieties obligatory 
 Reassessment of the human health limits set (ADI, OEL, etc) to include or set separate limits 
for nano-scale substances if necessary 
 Monitoring of exposure requires valid and suitable methods; exposure may have to be expressed 
in units other than mass, certainly for carbon nanotubes and NPs in the form of fibres. 
5.3 Overall conclusions 
1) In authorization procedures legislation, guidelines and guidance documents describe how and which 
toxicity tests should be performed. For NPs it is necessary to include herein that the physico-chemical 
parameters should include information on e.g. particle size, particle form, surface properties and 
other size properties that may influence the toxicity of the substance (see chapter 4.1). Furthermore 
appropriate dose metrics to use in the hazard characterization should be developed (see chapter 4.2 
and 4.3). Methodological changes in safety test protocols may be required to account for toxicity 
mechanisms of NPs not found in 'normal size' materials (see chapter 4.1). To assess the exposure of 
the food consumer to NPs it may also be necessary to investigate what the most appropriate dose 
metric would be (see chapter 4.4 and 4.5). 
2) For all substances for which an authorization procedure including toxicity testing has already been 
established before introduction onto the market, there is no need for new legislation in case of 
nanosizing of the substances, however re-evaluation of nanosized substances may be necessary. 
Nano-sized materials should therefore always be considered as 'new' (in all the legislation where a 
difference is made between 'existing' and 'new' substances). 
3) Adjustments of legislation, guidelines and guidance documents concerning the testing of the 
substance are necessary, especially concerning the physico-chemical characterization of the tested 
substance.  
4) Thresholds or limits set in different legislation that are expressed in concentrations of particular 
substances or via percentages or weight (e.g. maximum use level of an food additive, maximum limit 
for a contaminant, migration thresholds for food contact materials, and others) do not take into 
account the difference in properties of nanosized and non-nanosized substances. So thresholds or 
limits set already may be not appropriate for nanosized variants of the particular substances. 
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Annex 1 Inventory of applications of nanotechnol4ogy in the food chain 
6.1.1 Nanosensors 
Nanotechnology applied in agriculture. Terminology like precision farming is used, meaning that autonomous nanosensors are applied for real-time 
monitoring and early identification of plant health issues to take appropriate measures as early as possible. Use in early warning or emerging risk 
approaches can be foreseen. 
Sensors (including radio frequency identification technology) can also be incorporated into packaging materials (see packaging materials). Or sprayed 
directly on commodities. 
Product Basic element Function Illustration Other information Reference 
NanoBiolumines
cence Detection 
Spray 
 
Contains 
luminescent 
proteins that bind 
to the surface of 
Salmonella and E. 
coli 
When bound it emits 
a visible glow. In 
addition spray 
techniques are 
developed to apply 
these sensors in 
ocean freight 
containerized 
shipping 
  http://www.agromicron.com
/BTP.htm  
 
BioFinger Nano and micro 
cantilevers coated 
with antibodies 
Versatile, 
inexpensive, and 
easy-to-use 
diagnostic tools for 
health, 
enviroNPental and 
other applications 
In final developmental stage. 
Analysis based on the measurement 
of molecular interactions (ligand-
receptor interactions) by integrated 
micro- and nano-cantilever sensors. 
These are based on static and 
resonant cantilever arrays, which 
contain surface-stress or mass-
sensitive elements, respectively.  
 
http://www.iqe.ethz.ch/pel/r
esearch/biofinger.html 
 
 
                                                     
4
 Pictures in all tables of annex 1 are taken from the website that is referred to in the column reference of this table 
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6.1.2 Pesticides (delivery systems) 
Nanoformulations of pesticides are marketed and developed. In general the aim is to increase solubility in water, increase efficacy. Research is ongoing to 
develop encapsulates that are response to changes in the enviroNPent: e.g. humidity, pH etc. 
Product Basic 
element 
Form Size Function Other information Reference 
Nanoemulsion 
Primo MAXX® 
Trinexapac-
ethyl(cimecta
carb)  
micoremulsi
onconcentrat
e 
100NP mix completely with water and 
not settle out in a spray tank 
Registered for use in USA (some 
states) 
Syngenta 
http://www.syngentaprofessio
nalproducts.com/to/prod/prim
o/ 
Controlled 
release 
Karate®ZEON  
lambda-
cyhalothrin 
Quick-
Release 
Encapsulatio
n 
2.5 
micron 
Quick release. 
Improve residual function. 
Protection from UV 
Registered for use in USA, 
Germany, Brazil, France, 
India, Mexico, Indonesia, 
United Kingdom, Canada  
Syngenta 
http://www.syngentacropprote
ction-
us.com/prod/insecticide/Karat
e/  
Controlled 
release 
Demand® CS 
lambda-
cyhalothrin 
Encapsulatio
n 
2.5 
micron 
 Also for indoor use Syngenta 
http://www.syngentaprofessio
nalproducts.com/ppm/prod/de
mand/  
Iconet™ lambda-
cyhalothrin 
Encapsulatio
n 
2.5 
micron 
 Bednets repellent (Malaria) Syngenta 
http://www.syngenta.com/en/
products_services/icon_page.
aspx  
"gutbuster" Various 
active 
ingredients 
-- -- research on triggered-release 
capsules whose outer shell can 
be opened only in special 
conditions. 
R&D stage Syngenta 
http://www.syngenta.com/en/
day_in_life/microcaps.aspx  
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6.1.3 Water purification/ soil cleaning 
Purification of water which may be used in food production can involve filtering through nanofilters and purification due to reaction of contaminants with 
nano-sized metal particles. The latter method can in return be separated in catalysation or binding. The bioavailablity of the particles after binding is 
unknown. 
Product Basic 
element 
Form Size Charge Function Illustration Other information Reference 
Nanofiltration -- -- -- -- Filtering  Not known Generale des Eax + Filmtec 
www.nanoforum.org  
Nanofiltration 
NanoCeram 
Aluminium 
oxide 
2 NP AlO 
nanofibers 
-- -- Filtering   Argonide 
http://www.argonide.com/in
dex.htm  
Water cleaning 
Colloid  
Lanthanum 
particles 
-- -- -- 
Removing 
phosphates and 
arsenate 
  Altairno 
http://www.altairnano.com  
Soil cleaning Nanoscale 
iron powder 
-- -- -- Catalysing 
oxidation organic 
contaminants 
  Lehigh Universisty 
www.nanoforum.org  
Water cleaning 
(colloid) 
Nanoscale 
iron powder 
-- -- -- Binding and 
removing arsenic 
  Centre for Biological and 
EnviroNPental Nanotechnology 
www.nanoforum.org  
Filter systems and other purification techniques are being developed by many companies (e.g. BASF, DowChemicals) 
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6.1.4 Food processing and storage 
Mostly silver is used in processing/storage materials for its anti-bacterial properties, with exception of Zinc oxide in plastic wrapping. For Oil Fresh, the 
nano-element is unknown.  
Product Basic 
element 
Form Size Charge Function Illustration Other information Reference 
Nanoceramic 
inserts for 
deepfryers 
Unknown    Catalytically 
inhibiting thermal 
polymerization 
(molecules 
lumping together) 
process of the 
frying oil 
 
A flat, semi-
permanent, vertical 
insert, made of an 
advanced nanoceramic 
material. Authorized 
by the US FDA and 
certified by NSF Int'l. 
Oil fresh 
 
http://www.oilfresh.com/  
Antibacterial 
kitchen- and 
table ware 
Silver    Anti-bacterial 
 
 Nano Care technology 
http://www.nanocaretech.co
m/enyeNewsInfo.asp?id=17 
Silver nano baby 
bottle and baby 
mug cup 
Silver     
 
Through silver nano 
poly system 99.9% of 
germs are prevented 
and it maintains anti-
bacteria, deodorizing 
function as well as 
freshness. 
Baby dream 
 
http://babydream.en.ec21.co
m/  
Fresher longer 
Miracle food 
storage 
containers and 
bags 
Silver    Anti-bacterial 
 
Patent-pending silicone 
gasket locking system 
keeps out oxidizing air 
and antimicrobial 
silver nanoparticles in 
the polypropylene 
material reduce the 
growth of 
microorganisms. 
Sharper Image 
 
http://www.sharperimage.co
m/us/en/catalog/product/sku
__ZN020  
Nano plastic 
wrap 
ZnO    Anti-UV, reflecting 
IR, sterilizing and 
anti-mould, better 
temparture 
resistance, fire 
proof, bearing 
grinding 
 
 SongSing Nano Technology 
 
http://www.ssnano.net/ehtml
/detail1.php?productid=79  
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Nano silver tea 
pot 
Silver    Anti-bacterial, 
getting rid of bitter 
tea taste 
 SongSing Nano Technology 
 
http://www.ssnano.net/ehtml
/detail1.php?productid=73  
Nano silver 
spray 
Silver    Sterilization and 
deodorization 
 
 http://www.ssnano.net/ehtml
/detail1.php?productid=73  
Food Container 
(NS) 
Silver    Anti-bacterial 
 
 A-Do Global 
http://www.adox.info/?doc=
shop/list.php&ca_id=110  
Nano Silver 
Cutting Board 
Silver    Anti-bacterial 
 
 A-Do Global 
 
http://www.adox.info/?doc=
shop/item.php&it_id=00012
3  
Silver coatings 
in refrigerators 
Silver       LG, Samsung, Daewoo 
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6.1.5 Food packaging 
Smart packaging methods are developed to optimize shelf-life and improve food safety. These systems would be able to repair small holes, respond to 
enviroNPental conditions and alert the customer if the food is contaminated or spoiled. NPs included in plastic can increase barrier properties, and used to 
develop active antimicrobial and antifungal surfaces (www.nanoforum.org). 
Product Basic 
element 
Form Size Charge Function Illustration Other information Reference 
" electronic 
tongue" 
Nanosensor    Sensitve to gasses 
(spoiling of foods) 
  Kraft Foods a.o. 
www.nanoforum.org  
NanoBiolumines
cence Detection 
Spray 
 
    When bound it 
emits a visible 
glow. In addition 
spray techniques 
are developed to 
apply these sensors 
in ocean freight 
containerized 
shipping 
   
Durethan KU2-
2601 
Silicate NPs    Packaging film, 
barrier properties 
  BASF www.nanoforum.or g 
"Aegis" nylon 6 Nanocompos
ite 
   Increased barrier 
properties 
  Honeywell Speciality 
www.nanoforum.org  
Anitmicrobial 
films 
    Absorbs oxygen 
from the content of 
the package 
  Kodak www.nanoforum.org  
Imperm Nanocompos
ite containing 
clay NPs 
   Stonger bottles (for 
beer) 
  Voridan, Nanocor 
www.nanoforum.org  
Dirt repellent 
coatings 
e.g. 
Magnesium 
oxide 
Zinc oxide 
   'Lotus' effect 
Antimicrobial 
  www.nanoforum.org  
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6.1.6 Food commodities: Inert particles 
Product Basic 
element 
Form Size Charge Function Illustration Other information Reference 
Nano Cal/Mag Calcium and 
magnesium 
Unknown Unknown Unknown Enhanced uptake 
supplements 
 
From plant origen. http://www.mag-i-
cal.com/calciummagnesium.
htm#nanocalmag  
Silver 22 Silver Colloid Unknown Unknown Purifying and 
conservation of 
unknown targets. 
Solved in water, at 
concentration of 22 
ppm 
http://www.rbclifesciences.c
om/Products.aspx?ItemID=4
30  
Nanoceuticals 
Microhydrin 
Silicate Colloid Unknown Donates 
electrons 
Anti-oxidant and 
reducing surface 
tension of water 
 
Antioxidant by 
donating electrons and 
reducing surface 
tension of water from 
73 to 45 dynes 
http://www.rbclifesciences.c
om/Products.aspx?ItemID=1
61  
Nanosilicea 
kapseln 
Siliciumdioxi
de, 
magnesium 
and calcium 
Colloid Unknown Unknown Supporting cell 
structure and 
stability, and 
supporting 
physical condition. 
 
- http://www.neosino.com/ind
ex.php?id=695  
Sovereign Silver Silver Colloid Diameter 
0.8 NP  
Unknown Supporting 
immune system 
Concentration silver of 
10 ppm 
http://www.natural-
immunogenics.com/silver_
why_sovereign.php  
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Utopia silver 
supplements 
advanced 
colloidal silver 
Silver Colloid Unknown Unknown Supporting 
immune system 
 
Concentration silver of 
20 ppm 
http://www.utopiasilver.com
/products/silver/  
ASAP solutions Silver Colloid Unknown Unknown Supporting 
immune system 
 
10 ppm 
Producer claims in 
vitro and in vivo 
testing of product. 
http://www.nanoshop.com/li
sting/321/Engineered_silver
_nanoparticle_mineral_supp
lement.html  
 
http://www.asapsolution.co
m/  
Shetec Platinum 
water 
White gold Colloid 2 NP Unknown Anti-oxidant by 
reacting with free 
radicals. 
  Print GNDP database 
Biodream 
colloid plus 
Silver Colloid 5-15 NP Yes, but 
charge 
unknown 
Helpful against 
‘several ilnesses’ 
Unknown Unknown http://www.biodreamshop.nl
/UserFiles/File/Colloid_A5_
compleet.pdf 
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6.1.7 Food commodities: Carriers 
Product Basic element Form Size Charge Function Illustration Other information Reference 
Aquanova® 
Novasol® 
Micell   Diameter 
30 NP 
  100% water soluble, 
for solving normally 
insolvable substances. 
http://www.nanotechproject.o
rg/index.php?id=44&action=
view&product_id=1194  
Canola active 
oil 
Micell  Unknown  Loaded with 
phytosterols 
 
Replaces cholesterol in 
bile acid micells, 
preventing uptake in 
the blood. 
http://www.nanotechproject.o
rg/index.php?id=44&action=
view&product_id=1019  
LifePak Nano CR6- 
liponutrients 
 Unknown  Loaded with anti-
oxidants, vitamins 
and minerals 
Supplement ‘on 
demand’, anything can 
be incorporated in the 
CR6 membrane. 
http://www.pharmanex.com/
intercom/productDetail.do?p
rodId=01003610&mktId=20
31  
  
Nanoceuticals 
Chocolate Slim 
Shake  
Nanoclusters 
(contents 
unknown) 
 Unknown  Enhancing cocoa 
flavour and uptake 
of supplemented 
soy and whey 
proteins. 
  
According to the 
producer, nanoclusters 
are tiny particles, 
100,000th the size of a 
single grain of sand, 
and are designed to 
carry nutrition into 
your cells. 
http://www.rbclifesciences.c
om/Products.aspx?ItemID=3
8  
 RIKILT /RIVM Report 2007.014 84 
Nutralease 
nano-sized self-
assembled 
liquid structures 
(NSSL) 
supplements 
Micell  30 NP  Delivery system 
 
Coined fortified nano-
vehicles.  
 
http://www.nutralease.com/t
echnology.asp, 
Solgar Nutri 
Nano Co Q10 
Micell  30 NP  Enhanced uptake 
of Coenzym Q10 
 
- http://www.nanoshop.com/li
sting/59/Nano_nutritional_s
upplements.html  
Tip Top Bread Micell  Unknown  Uptake of tuna oil 
with omega 3 fatty 
acids without tastin 
git. 
 -  http://www.tiptop.com.au/dr
iver.asp?page=main/product
s/bread/up+wholemeal+ome
ga+3+dha  
cheese liposome    Entrapment of 
proteolitic 
enzymes in cheese 
produktion 
  (Mozafari et al. 2006) 
 liposomes    Facilating 
intracellular uptake 
and extending the 
half live of 
encapsulated 
antioxidants 
  (Mozafari et al. 2006) 
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 Archaeosome
s 
   Protect 
antioxidants during 
food processing 
and show great 
promise as an oral 
delivery system for 
bioactive agents. 
 Relatively 
thermostable, resistant 
to oxidation and 
enzymatic hydrolysis, 
low pH and bilesalts. 
(Mozafari et al. 2006) 
 Nanocochleat
es 
Cigar 
shaped 
  Delivery system 
for hydrophobic, 
amphiphylic, neg. 
or pos charged 
molecules and 
resistant in the 
gastrointestinal 
tract 
  (Mozafari et al. 2006) 
 Liposomes     Encapsulation of 
-tocopherol 
 The disappearance rate 
after oral dose of 
5,0000 U to cows of 
-tocopherol was less 
when encapsulated in 
liposomes bud not 
significant.  
(Bontempo et al. 2000) 
 Liposomes 
Based on a 
natural 
mixture of 
marine lipids 
   Delivery of pufa 
by the oral route 
 Marine lipids 
constituted an 
attractive material for 
the development of 
liposomes 
(Nacka et al. 2001) 
 chitosan sperical 100-200 
nm 
 Carrier in oral 
allergen-gene 
immunization to 
treat food allergy 
  (Roy et al. 1999) 
cheese liposomes    Entrapment of 
encapsulated 
proteinases and 
lipases during 
cheese ripening 
  (Taylor et al. 2005) 
Dairy products liposomes    Fortify products 
with vitamins as 
well as aid in 
digestion and 
protection against 
degradation 
  (Taylor et al. 2005) 
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 Liposomes of 
marine 
phospholipids 
   Oral PUFA 
supplement 
  (Cansell et al. 2003) 
 Polystyrene  spheres 50nm-
3m 
   Daily dose of 1.25 mg 
by oral gavage to rats 
50 and 100 nm 
particles were 
absorbed and found in 
blood 
Halbert 1990 
Reviewed by 
(Hoet et al. 2004) 
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6.1.8 Food commodities: Other applications 
Product Basic element Size Function Illustration Other information Reference 
ASN advanced 
sports nutrition 
supplements  
Nanosized 
particle 
Under 1 
µm 
Advanced 
absorption 
 
Nanosized creatine 
particles, isolated from 
micronized creatinine. 
http://www.asn-
nutrition.com/nano_technology.htm 
 
C.L.E.A.N. 
products (1-8) 
Regulatory 
peptides from 
plants 
0.01 – 0.1 
NP 
Supporting 
several body 
functions 
 
To be solved in water.  https://www.sportmedix.com/index.php?lang=engli
sh&page=products&dlei_pp=1  
Nanotechspray 
(oral dosing) 
Nanodroplets 87 NP Enhanced 
uptake of 
vitamin B12 
and other 
supplements  
 
Nanodroplets are 
produced by 
nanotechnology in the 
spraying system. 
http://www.nutritionbynanotech.com/product_line.
htm  
Artichoke 
nanoclusters, 
Spirulina 
nanoclusters 
Nanoclusters Unknown Supporting 
liver function, 
improvement 
of skin and 
support of total 
condition. 
 
RBC lifsciences 
produces several types of 
NanoCeuticals. The 
‘nanoclusters’ consist of 
potassium citrate, 
potassium carbonate, 
silica, purified water, 
magnesium sulfate and 
sunflower oil. 
http://www.rbclifesciences.com/Products.aspx?Ite
mID=118  
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Shenzhen 
Nanotea 
Nanomilled tea <100NP Enhanced 
uptake of tea 
ingredients. 
 
Nanomilled tea. http://www.nanotechproject.org/index.php?id=44&
action=view&product_id=1228  
 
www.369.com.cn/En/nanotea.htm 
 
https://www.uknow.or.jp/be/science/seminar/nanot
ech_business/simon_holland.pdf  
Spray for life 
Vitamin 
supplements 
Nanodroplets 0.188 NP 
and 
5.421µm? 
Enhanced 
uptake 
 
According to producer, 
Nanodroplets™ are 
made by a patented 
nanosuspension process, 
which allows molecules 
to be embedded into 
micro and 
Nanodroplets™ at an 
average of 0.188 NP and 
5.421µm in size, which 
are used to create stable, 
uniform and highly 
soluble emulsions and 
dispersions. 
http://www.healthplusintl.com/products.html 
 
Nanoscale 
coating 
Variable Unknown Accurate 
coating of food 
products 
 
Ultrasonic spraying 
systems are used to 
accurately put natural 
anti-bacterial coats on 
food products. The 
process was also used 
with natural oils and 
various glazing and 
decorating compounds. 
http://www.foodqualitynews.com/news/ng.asp?n=7
6650&m=2FQN518&c=gqcohokhydnruud 
 
http://www.sono-tek.com/widetrack/index.php 
 
Nanoceuticals 
Hydracell 
Nanoclusters Unknown Reducing 
surface tension 
of water. 
 
Reduces the surface 
tension of water from 74 
dynes to 59 dynes. The 
mechanism is not 
mentioned. 
http://www.rbclifesciences.com/Products.aspx?Ite
mID=142  
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Nano Water Waterclusters Unknown Enhanced 
uptake of water 
 According to producer, 
Nanowater is processed 
by the Nanometer high-
energy water activator 
which enhances the 
activity of water 
molecule clusters and 
shrinks the molecule 
clusters so that the 
infiltration pressure is 
strengthened and that the 
speed of movement of 
the small water molecule 
clusters is increased. 
http://www.nanotech.com.hk/en/first.html 
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Annex 2: Summaries of available oral toxicity studies 
(Chen et al. 1998)studied the acute and subacute toxicity of C60 polyalkylsulfonate in rats. No mortality 
was observed in an acute oral toxicity test with doses up to 2500 mg/kg. After ingestion, NPs may cross 
the gut barrier and can be distributed to various organs depending on their size. There is insufficient 
evidence to determine whether NPs adversely affect the gut or the organs they are distributed to (Tran et 
al., 2005; UBA, 2006).  
 
(Wang et al. 2006)studied the acute toxicity of oral exposure to nanoscale zinc powder compared to 
microscale zinc powder in mice. The mice were gastrointestinally administered at a dose of 5 g/kg body 
weight. The nanoscale zinc treated mice showed more severe symptoms of lethargy, vomiting and 
diarrhea in the beginning days than the microscale zinc treated mice. Deaths of two (of the ten) mice 
occurred in the nanoscale zinc group after the first week of treatment due to intestinal obstruction of the 
nanoscale zinc aggregation. Clinical changes and biochemical liver function tests of serum indicated 
that microscale zinc powder induced more severe liver damage than nanoscale zinc powder. 
Histopathological examinations showed severe renal damage in the nanoscale zinc treated mice, without 
significant changes of blood biochemical levels. Blood-element test indicated that nanoscale zinc 
powder could cause severe anemia. Besides the pathological lesions in the liver, renal, and heart tissue, 
only slight stomach and intestinal inflammation was found in all the zinc treated mice, without 
significant pathological changes in other organs. 
 
The toxicity of copper NPs (23.5 NP) exposed to mice by oral gavage was compared with that of copper 
micro-particles (17µm) and cupric ions (CuCl2·2H2O) (Chen et al., 2006). The LD50s of 23.5 NP, 17 
µm copper particles and cupric ions were determined to be 413, >5000 and 110 mg/kg body weight, 
respectively. The pathological examinations revealed that kidney, liver and spleen are target organs for 
nano-copper particles. These were further demonstrated by measurements of the blood biochemical 
indexes (BUN, Cr, TBA and ALP) reflecting the renal and hepatic functions of experimental mice. 
Pathological changes and grave injuries on kidney, liver and spleen were observed in mice exposed to 
23.5 NP nano-copper particles (e.g., swelling up and dwindling in gap of renal glomerulus, degeneration 
and irreversibly massive necrobiosis of epithelial cells of renal proximal convoluted tubules, reducing 
karyons of epithelial cells of renal tubules, proteinic liquid in renal tubules, purple deposition in the 
proteinic liquid, the steatosis around venae centrals of hepatic tissue, etc.), but they were not found in 
mice exposed to 17 µm copper particles on mass basis. In addition, toxicity of nanocopper is sex-
dependent: male mice exhibit more severe toxic symptoms and suffer more from nanocopper than 
females after they exposed to the same mass of particles.  
Wang et al. (2007) investigated the acute oral toxicity of 25, 80 NP and fine (155 NP) TiO2 particles 
was investigated according to the standard procedure (OECD Guidelines, No. 420) for testing the 
chemicals. No obvious acute toxicity was observed after a single oral exposure to 5 g/kg TiO2 particles. 
However, the female mice showed higher coefficients of liver in the nano-sized (25 and 80 NP) groups 
than the fine group. The changes of serum biochemical parameters (ALT/AST, LDH) and pathology 
(hydropic degeneration around the central vein and the spotty necrosis of hepatocytes) of liver indicated 
that the hepatic injury was induced after exposure to mass different-sized TiO2 particles. In addition, the 
nephrotoxicity like increased BUN level and pathology change of kidneys was also observed in the 
experimental groups. The significant change of serum LDH and alpha-HBDH in 25 and 80 NP groups 
showed the myocardial damage compared with the control group. However, there are no abnormal 
pathology changes in the heart, lung, testicle (ovary), and spleen tissues. Biodistribution experiment 
showed that TiO2 mainly retained in the liver, spleen, kidneys, and lung tissues, which indicated that 
TiO2 particles could be transported to other tissues and organs after uptake by gastrointestinal tract.  
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(Zhang et al. 2001)showed that Nano-Se had lower acute toxicity as compared with selenite in mice 
(LD50: 113.0 vs. 15.7 mg/kg bw Se). However the bioavailability of selenite was similar in terms of 
inducing seleno-enzymes in cultured cells and in Se-deficient rats. 
Zhang et al., (2005) compared the short-term toxicity of both selenite and Nano-Se in mice. An oral 
dose of 2, 4 and 6 mg selenite or Nano-Se /kg bw per day was administered for consecutive 12 or 15 
days. Nano-Se is less toxic than selenite in short-term/large dose treatments as shown by ameliorated 
suppression of growth, moderate redox stress, and liver toxicity (lower levels of ALT and AST).  
 
(Jia et al. 2005)compared the subchronic toxicity of Nano-Se with selenite and high-selenium protein in 
rats. Groups of Sprague-Dawley rats (12 males and 12 females per group) were fed diets containing 
Nano-Se, selenite and highselenium protein at concentrations of 0, 2, 3, 4 and 5 ppm Se, respectively, 
for 13 weeks. At the two higher doses (4 and 5 ppm Se), significant abnormal changes were found in 
body weight, hematology, clinical chemistry, relative organ weights and histopathology parameters. 
However, the toxicity was more pronounced in the selenite and high-selenium protein groups than the 
Nano-Se group. At the dose of 3 ppm Se, significant growth inhibition and degeneration of liver cells 
were found in the selenite and high-selenium protein groups, but not in the Nano-Se group. In 
conclusion, Nano-Se is less toxic than selenite and high-selenium protein in the 13-week rat study. 
 
In studies with cationic PAMAM dendrimers, Duncan et al. ((Duncan and Izzo 2005)) administered 
generations 3, 5 and 7 to mice at doses of 2.6, 10 and 45 mg/kg, respectively. The dendrimers were 
given either as single dose or repeatedly once a week for 10 weeks. Although no behavioural changes or 
weight loss was reported over a 2 h period, after administration of generation 7 three animals died. In 
the multiple dose study a degree of liver cell vacuolation was also observed during histopathology and 
this would be consistent with a lysosomal storage problem. Further studies are needed to verify these 
findings (Duncan et al., 2005). 
Carrero-Sanchez et al., (2006) compared the toxicological effects between pure carbon multiwalled 
nanotubes (MWNTs) and N-doped multiwalled carbon (CNx) nanotubes. Different doses of tubes were 
administered in various ways to mice: nasal, oral, intratracheal, and intraperitoneal. When MWNTs were 
injected into the mice's trachea, the mice could die by dyspnea depending on the MWNTs doses. 
However, CNx nanotubes never caused the death of any mouse. CNx nanotubes were far more tolerated 
by the mice when compared to MWNTs. Extremely high concentrations of CNx nanotubes 
administrated directly into the mice's trachea only induced granulomatous inflammatory responses. 
Importantly, all other routes of administration did not induce signs of distress or tissue changes on any 
treated mouse. These results indicate that CNx nanotubes are less harmful than MWNTs or SWNTs.  
 
(Xia 2005)studied the acute toxicology of nano-magnetic ferrofluid. The effective diameter of the 
magnetic particles was about 19.9 NP, and the concentration of the ferrofluid was 17. 54 mg/ml. The 
acute toxic reaction and the main viscera pathological morphology of mice were evaluated after oral, 
intravenous and intraperitoneal administration of the nano-magnetic ferrofluid of different doses 
respectively. Half lethal dose (LD50) > 2104. 8 mg/kg, maximum non-effect dose (ED0) = 320. 
10mg/kg with oral; LDs,> 438. 50 mg/kg, EDo = 160. 05 mg/kg with intravenous route; and LDso 
>1578. 6 mg/kg, ED0 = 320. 10 mg/kg with intraperitoneal administration. Degeneration and necrosis 
of viscera were not found. These results indicate that the acute toxicity of nano-magnetic ferrofluid is 
very low.  
